

**Defendants' Exhibit List (Ex. A)**Case # **2:16-cv-02525-MMD-NJK**Caption: Amarin Pharma, Inc. v. Hikma  
Pharmaceuticals USA, Inc., et al.**Exhibits for:** Defendants Hikma Pharmaceuticals USA, Inc.; Hikma Pharmaceuticals International Limited; Dr. Reddy's Laboratories, Inc.; and Dr. Reddy's Laboratories, Ltd.

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1500		U.S. Patent No. 8,293,728 (AMRN-PEXP-0000001-22)
1/8/2020		1501		U.S. Patent No. 8,293,728 File History (AMRN00206053-212773)
1/8/2020		1502		U.S. Patent No. 8,318,715 (AMRN-PEXP-0000023-45)
1/8/2020		1503		U.S. Patent No. 8,318,715 File History (AMRN00212774-19280)
1/8/2020		1504		U.S. Patent No. 8,357,677 (AMRN-PEXP-0000046-67)
1/8/2020		1505		U.S. Patent No. 8,357,677 File History (AMRN00219281-25724)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1506		U.S. Patent No. 8,367,652 (AMRN-PEXP-0000068–90)
1/8/2020		1507		U.S. Patent No. 8,367,652 File History (AMRN00225725-32139)
1/8/2020		1508		U.S. Patent No. 8,377,920 (AMRN-PEXP-0000091–113)
1/8/2020		1509		U.S. Patent No. 8,377,920 File History (AMRN00232140-9831)
1/8/2020		1510		U.S. Patent No. 8,399,446 (AMRN-PEXP-0000114–36)
1/8/2020		1511		U.S. Patent No. 8,399,446 File History (AMRN00239832-47573)
1/8/2020		1512		U.S. Patent No. 8,415,335 (AMRN-PEXP-0000137–60)
1/8/2020		1513		U.S. Patent No. 8,415,335 File History (AMRN00247574-55303)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1514		U.S. Patent No. 8,431,560 (AMRN-PEXP-0000161-83)
1/8/2020		1515		U.S. Patent No. 8,431,560 File History (AMRN00263074-71241)
1/8/2020		1516		U.S. Patent No. 8,518,929 (AMRN-PEXP-0000184-206)
1/8/2020		1517		U.S. Patent No. 8,518,929 File History (AMRN00287378-988)
1/8/2020		1518		U.S. Patent No. 8,524,698 (AMRN-PEXP-0000207-30)
1/8/2020		1519		U.S. Patent No. 8,524,698 File History (AMRN00287989-8608)
1/8/2020		1520		U.S. Patent No. 8,293,727 (AMRN03061427-47)
1/8/2020		1521		U.S. Patent No. 8,293,727 File History (AMRN03058106-9969)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1522		U.S. Provisional Application Nos. 61/151,291 (AMRN00204453-503)
1/8/2020		1523		U.S. Provisional Application Nos. 61/173,755 (AMRN00204504-557)
1/8/2020		1524		WO 2007/142118 and English translation (ICOSAPENT_DFNDTS00007058-107)
1/8/2020		1525		WO 2008/004900 (ICOSAPENT_DFNDTS00007108-50)
1/8/2020		1526		National Institutes of Health, National Heart, Lung, and Blood Institute, "Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, Executive Summary," May 2001) (ICOSAPENT_DFNDTS00006549-87)
1/8/2020		1527		"Epadel Capsules 300, Japan Pharmaceutical Reference 369 (2nd ed. 1991) (ICOSAPENT_DFNDTS00006169-73)
1/8/2020		1528		Epadel Capsules 300, January 2007 Update (Version 5) (ICOSAPENT_DFNDTS00008961-969)
1/8/2020		1529		Geppert et al., Microalgal Docosaheanoic Acid Decreases

Date Marked	Date Admitted	Number	Witness	Description
				Plasma Triacylglycerol in Normolipidaemic Vegetarians: A Randomized Trial, 95 BRIT. J. NUTRITION 779 (2006) (ICOSAPENT_DFNDTS00006126-35)
1/8/2020		1530		"Grimsgaard et al., Highly Purified Eicosapentaenoic Acid and Docosaheptaenoic Acid in Humans Have Similar Triacylglycerol-Lowering Effects but Divergent Effects on Serum Fatty Acids, 66 AM. J. CLIN. NUTR. 649-59 (1997) (ICOSAPENT_DFNDTS00006136-46)
1/8/2020		1531		Harris et al., Safety and Efficacy of Omacor in Severe Hypertriglyceridemia, J. CARDIOV. RISK, 4:385-391 (1997) (ICOSAPENT_DFNDTS00006152-58)
1/8/2020		1532		Hayashi et al., Decreases in Plasma Lipid Content and Thrombotic Activity by Ethyl Icosapentate Purified from Fish Oils, 56(1) CURR. THERAP. RES. 24-31 (1995) (ICOSAPENT_DFNDTS00006159-68)
1/8/2020		1533		Katayama et al., Efficacy and Safety of Ethyl Icosapentate (Epadel®) Given for a Long Term Against Hyperlipidemia, 21 PROG. MED. 457 (2001) and English translation (ICOSAPENT_DFNDTS00006174-6200)
1/8/2020		1534		Kurabayashi et al., Eicosapentaenoic Acid Effect on Hyperlipidemia in Menopausal Japanese Women. OBSTET. GYNECOL. 96:521-8 (2000) (ICOSAPENT_DFNDTS00006237-44)
1/8/2020		1535		Lovaza®, Physicians' Desk Reference 2699 (62d ed. 2007)

Date Marked	Date Admitted	Number	Witness	Description
				(ICOSAPENT_DFNDTS00006710-13)
1/8/2020		1536		Maki et al., Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol, 24 J. AM. COL. NUTR. 189-99 (2005)
				(ICOSAPENT_DFNDTS00006426-36)
1/8/2020		1537		Matsuzawa et al., Effect of Long-Term Administration of Ethyl Icosapentate (MND-21) in Hyperlipidaemic Patients, 7 J. CLIN. THERAPEUTIC & MEDICINES 1801 (1991) and English translation
				(ICOSAPENT_DFNDTS00006440-96)
1/8/2020		1538		Mori et al., Purified Eicosapentaenoic and Docosahexaenoic Acids Have Differential Effects on Serum Lipids and Lipoproteins, LDL Particle Size, Glucose, and Insulin in Mildly Hyperlipidemic Men, 71 AM. J. CLINICAL NUTRITION 1085 (2000)
				(ICOSAPENT_DFNDTS00011026-35)
1/8/2020		1539		Nakamura et al., Joint Effects of HMG-CoA Reductase Inhibitors and Eicosapentaenoic Acids on Serum Lipid Profile and Plasma Fatty Acid Concentrations in Patients with Hyperlipidemia, 29(1) INT. J. CLIN. LAB. RES. 22-25 (1999)
				(ICOSAPENT_DFNDTS00006540-43)
1/8/2020		1540		Nestel et al., The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. 76 AM. J. CLIN. NUTR. 326 (2002)
				(ICOSAPENT_DFNDTS00006544-48)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1541		Nozaki et al., Effects of Purified Eicosapentaenoic Acid Ethyl Ester on Plasma Lipoproteins in Primary Hypercholesterolemia, 62 INT'L J. VITAMIN & NUTRITION RES. 256-60 (1992) (ICOSAPENT_DFNDTS00006588-94)
1/8/2020		1542		Okumura et al., Eicosapentaenoic Acid Improves Endothelial Function in Hypertriglyceridemic Subjects Despite Increased Lipid Oxidizability, 324 AM. J. MED. SCI. 247-53 (2002) (ICOSAPENT_DFNDTS00006595-6601)
1/8/2020		1543		Omacor® Label (2004) (ICOSAPENT_DFNDTS00006618-26)
1/8/2020		1544		Omacor®, Physicians' Desk Reference 2735 (60d ed. 2006) (ICOSAPENT_DFNDTS00006714-17)
1/8/2020		1545		Park & Harris, Omega-3 Fatty Acid Supplementation Accelerates Chylomicron Triglyceride Clearance, 44 J. LIPID RES. 44:455-463 (2003) (ICOSAPENT_DFNDTS00006701-6709)
1/8/2020		1546		Saito et al., Results of Clinical Usage of Improved Formulation (MND-21S) Epadel Capsule 300 with Respect to Hyperlipidemia, 26(12) JPN. PHARMACOL. THER. 2047-62 (1998) and English translation (ICOSAPENT_DFNDTS00006791-6823)
1/8/2020		1547		Saito et al., Effects of EPA on Coronary Artery Disease in

Date Marked	Date Admitted	Number	Witness	Description
				Hypercholesterolemic Patients with Multiple Risk Factors: Sub-Analysis of Primary Prevention Cases from the Japan EPA Lipid Intervention Study (JELIS), 200 ATHEROSCLEROSIS 135-40 (2008) (ICOSAPENT_DFNDTS00006785-90)
1/8/2020		1548		Satoh et al., Purified Eicosapentaenoic Acid Reduces Small Dense LDL, Remnant Lipoprotein Particles, and C-Reactive Protein in Metabolic Syndrome, 30 DIABETES CARE 144 (2007) (ICOSAPENT_DFNDTS00006832-36)
1/8/2020		1549		Shinozaki et al., The Long-Term Effect of Eicosapentaenoic Acid on Serum Levels of Lipoprotein (a) and Lipids in Patients with Vascular Disease, 2(2) J. ATHEROSCL. THROMB. 107-09 (1996) (ICOSAPENT_DFNDTS00011751-3)
1/8/2020		1550		Takaku et al., Study on the Efficacy and Safety of Ethyl Icosapentate (MND-21) in Treatment of Hyperlipidemia Based on a Long-Term Administration Test, 7 J. CLIN. THERAPEUTICS & MEDICINE 191 (1991) and English translation (ICOSAPENT_DFNDTS00006864-6904)
1/8/2020		1551		Wojenski et al., Eicosapentaenoic Acid Ethyl Ester as an Antithrombotic Agent: Comparison to an Extract of Fish Oil, BIOCHIM. BIOPHYS. ACTA., 1081(1):33-38 (1991) (ICOSAPENT_DFNDTS00014511-6)
1/8/2020		1552		Yokoyama et al., Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: Rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS), 146 AM.



Date Marked	Date Admitted	Number	Witness	Description
				HEART J. 613-20 (2003) (ICOSAPENT_DFNDTS00007166-73)
1/8/2020		1553		Yokoyama et al., Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): a Randomized Open-Label, Blinded Endpoint Analysis, 369 LANCET 1090-98 (2007) (ICOSAPENT_DFNDTS00007157-65)
1/8/2020		1554		Opening Expert Report of Matthew Budoff, M.D., Regarding Hikma's ANDA product and Vascepa® with Exhibits A-C
1/8/2020		1555		Opening Expert Report of Matthew Budoff, M.D., Regarding DRL's ANDA product and Vascepa®
1/8/2020		1556		Reply Expert Report of Matthew Budoff, M.D., Regarding Defendants' ANDA Products and Vascepa® and Exhibits A-B
1/8/2020		1557		Email between Ketchum and Budoff re Vascepa (icosapent ethyl) [formerly AMR101]: Congressional Heart and Stroke Coalition (AMRN02712524-26)
1/8/2020		1558		FDA Complete Response, NDA 202057/S-005 (AMRN03132005-09)
1/8/2020		1559		Dollars for Docs: 2015 Edition

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1560		OpenPaymentsData.CMS.gov 2016 data for Matthew J. Budoff Summary
1/8/2020		1561		OpenPaymentsData.CMS.gov 2016 data for Matthew J. Budoff General Payments
1/8/2020		1562		OpenPaymentsData.CMS.gov 2017 data for Matthew J. Budoff General Payments
1/8/2020		1563		OpenPaymentsData.CMS.gov 2018 data for Matthew J. Budoff General Payments
1/8/2020		1564		Investigator Services Agreement (AMRN03171996-2021)
1/8/2020		1565		Amendment #1 to Investigator Services Agreement (AMRN03172022-29)
1/8/2020		1566		Amendment #2 to Investigator Services Agreement (AMRN03172030-34)
1/8/2020		1567		Amendment #3 to Investigator Services Agreement (AMRN03172035-42)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1568		Amendment to Speaker Services Agreement of 2014 (AMRN03172043)
1/8/2020		1569		Services Agreement (AMRN03172044-48)
1/8/2020		1570		Services Agreement (AMRN03172049-51)
1/8/2020		1571		Consultancy Agreement (AMRN03172052-60)
1/8/2020		1572		Amarin Mutual Confidentiality Agreement (AMRN03172061-64)
1/8/2020		1573		Consultancy Agreement (AMRN03172065-73)
1/8/2020		1574		Responsive Expert Report of Edward A. Fisher, M.D., M.P.H., Ph.D.
1/8/2020		1575		List of Materials Considered by Dr. Edward A. Fisher

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1576		Curriculum Vitae of Edward A. Fisher, M.D., M.P.H., Ph.D.
1/8/2020		1577		Feingold and Grunfeld, Diabetes and Dyslipidemia. NCBI Bookshelf. <a href="https://www.ncbi.nlm.nih.gov/books/NBK305900/?report=printable">https://www.ncbi.nlm.nih.gov/books/NBK305900/?report=printable</a> (last accessed 06/25/2019)
1/8/2020		1578		Lovaza® Label (AMRN01187779-80)
1/8/2020		1579		Chapman, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 32:1345-1361 (2011).
1/8/2020		1580		American Diabetes Association, 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2019. Diabetes Care 42(1): S103-S123 (January 2019). (AMRN-PEXP-0008656-81)
1/8/2020		1581		O’Riordan, MARINE: Ethyl-EPA Reduces Triglyceride Levels Without Raising LDL Cholesterol. <a href="http://www.medscape.com">www.medscape.com</a> (November 30, 2010). (AMRN00291600-602)
1/8/2020		1582		Siscovick, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation

Date Marked	Date Admitted	Number	Witness	Description
				135:e867-e8884 (2017). (ICOSAPENT_DFNDTS00018006-23)
1/8/2020		1583		Reply Expert Report of Nicholas P. Godici with Exhibits A-C.
1/8/2020		1584		Expert Report of Stephen G. Kunin
1/8/2020		1585		Non-Final Rejection, U.S. Patent Application No. 12/702,889. (AMRN03058824-35)
1/8/2020		1586		Response to the Office Action Dated June 20, 2011, U.S. Patent Application No. 12/702,889. (AMRN03058867-907)
1/8/2020		1587		Final Rejection, U.S. Patent Application No. 12/702,889. (AMRN03059004-28)
1/8/2020		1588		Non-Final Rejection, U.S. Patent Application No. 12/702,889. (AMRN03059744-69)
1/8/2020		1589		Declaration of Philip Lavin under 37 C.F.R. §1.132, U.S. Patent Application No. 12/702,889. (AMRN03059830-34)
1/8/2020		1590		Interview Agenda and Summary, U.S. Patent Application No. 12/702,889.

Date Marked	Date Admitted	Number	Witness	Description
				(AMRN03059782-88)
1/8/2020		1591		Notice of Allowance, U.S. Patent Application No. 12/702,889. (AMRN03059927-40)
1/8/2020		1592		37 CFR 1.104 Nature of examination Rev. 5, Aug. 2006
1/8/2020		1593		Declaration III of Harold E. Bays Under 37 C.F.R. § 1.132, U.S. Patent Application No. 12/702,889. (AMRN03059815-23)
1/8/2020		1594		In Limine Order Granting Defendant Medtronic's Motion to Exclude the Testimony of Nicholas Godici, Barry v. Medtronic. E.D. Tex. No. 1:14-cv-104
1/8/2020		1595		Opening Expert Report of Jay W. Heinecke, M.D. on Invalidity of the Asserted Claims of the Patents-In-Suit with Exhibits 1-2.
1/8/2020		1596		Rebuttal Expert Report of Jay W. Heinecke, M.D. on Invalidity of the Asserted Claims of the Patents-In-Suit with Materials Considered
1/8/2020		1597		Reply Expert Report of Jay W. Heinecke, M.D. on invalidity of the Asserted Claims of the Patents-In-Suit with Materials Considered
1/8/2020		1598		TRICOR® Approved Labeling (AMRN-PEXP-0001915-32)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1599		Niaspan® Label (AMRN-PEXP-0001692-1712)
1/8/2020		1600		Carlson, et al. ON the Rise in Low Density and High Density Lipoproteins in Response to the Treatment of Hypertriglyceridaemia in Type IV and Type V Hyperlipoproteinaemias. Atherosclerosis 26:603-609 (1977). (AMRN-PEXP-0008180-86)
1/8/2020		1601		Isley, et al. Pilot study of combined therapy with w-3 fatty acids and niacin in atherogenic dyslipidemia, Journal of Clinical Lipidology 1:211-217 (2007). (AMRN-PEXP-00621043-49)
1/8/2020		1602		Mitchell, Peter. Regulator rebuffs Merck's cholesterol drug. <a href="http://chemistryworld.com/news/regulator-rebuffs-mercks-cholesterol-drug/3003426.article">chemistryworld.com/news/regulator-rebuffs-mercks-cholesterol-drug/3003426.article</a> (AMRN-PEXP-0009429-31)
1/8/2020		1603		European Medicines Agency press release, Tredaptive, Pelzont and Trevaclyn suspended across the EU. (AMRN-PEXP-0009110-12)
1/8/2020		1604		Oram and Heinecke, When Good Cholesterol Turns Bad: The Evolving Saga of CETP Inhibitors and Clinical Strategies to Elevate High-density Lipoprotein. Current Atherosclerosis Reports 9:425-427 (2007).
1/8/2020		1605		Schacky, A review of omega-3 ethyl esters for cardiovascular prevention

Date Marked	Date Admitted	Number	Witness	Description
				and treatment of increased blood triglyceride levels. Vascular Health and Risk Management 2(3):251-262 (2006). (AMRN-PEXP-0007466-77)
1/8/2020		1606		Rebuttal Expert Report of Ivan T. Hofmann with Appendices 1-3
1/8/2020		1607		Spreadsheet: Treatment Insights View (AMRN-PEXP-0007104)
1/8/2020		1608		Spreadsheet: Historical Revenue Historical Revenue Q1 2013-Q4 2018 (AMRN03171431)
1/8/2020		1609		Spreadsheet: Rx View (AMRN-PEXP-0007102)
1/8/2020		1610		Opening Expert Report of Firhaad Ismail, M.D., F.A.C.E. with Exhibits A-B
1/8/2020		1611		Corrected Opening Expert Report of Firhaad Ismail, M.D., F.A.C.E.
1/8/2020		1612		Reply Expert Report of Firhaad Ismail, M.D., F.A.C.E. with Exhibit A



Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1613		Speaker Services Agreement (AMRN03171905-13)
1/8/2020		1614		2014 Speaker Contract (AMRN03171896-1904)
1/8/2020		1615		Speaker Services Agreement (AMRN03171914-20)
1/8/2020		1616		2016 Speaker Services Agreement (AMRN03171921-26)
1/8/2020		1617		Ornstein, et al. Dollars for Doctors. Docs on Pharma Payroll Have Blemished Records, Limited Credentials. <a href="https://www.propublica.org/article/dollars-to-doctors-physician-disciplinary-records#">https://www.propublica.org/article/dollars-to-doctors-physician-disciplinary-records#</a> (last accessed 6/11/19)
1/8/2020		1618		Dollars for Docs, Top Earners. <a href="https://web.archive.org/web/20110715123145/http://projects.propublica.org/docdollars/top_earners">https://web.archive.org/web/20110715123145/http://projects.propublica.org/docdollars/top_earners</a>
1/8/2020		1619		State of Nevada Pharmacy & Therapeutics Committee Meeting Minutes
1/8/2020		1620		Email between Riedell and Meehan re Summary & Next Steps: Vascepa

Date Marked	Date Admitted	Number	Witness	Description
				Speaker Programs (AMRN00974580)
1/8/2020		1621		Spreadsheet: Controlled List Speakers 05172011 (AMRN00974582)
1/8/2020		1622		Email between Padmanabhan and Budsock (AMRN02390922)
1/8/2020		1623		Spreadsheet of consultant payments (AMRN02390926)
1/8/2020		1624		Tajuddin, et al. Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2016:9 109-118. (AMRN-PEXP-0001808-17.)
1/8/2020		1625		Reply Expert Report of John Kornak, Ph.D. with Exhibits A-B
1/8/2020		1626		Corrected Reply Expert Report of John Kornak, Ph.D. with Exhibits A-B
1/8/2020		1627		Redlined Corrected Reply Expert Report of John Kornak, Ph.D. with Exhibits A-B

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1628		document titled lavinV3 ICOSAPENT_DFNDT 00020685.R
1/8/2020		1629		document titled reportPlots ICOSAPENT_DFNDT 00020684.R
1/8/2020		1630		document titled lavinV5 ICOSAPENT_DFNDT 00020683.R
1/8/2020		1631		document titled lavinV5 ICOSAPENT_DFNDT 00020683.R Calculations
1/8/2020		1632		Miller, et al. Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 123:2292-2333 (2011). (ICOSAPENT_DFNDT00020641-82)
1/8/2020		1633		Carroll, et al. Trends in Lipids and Lipoproteins in U.S. Adults, 1988-2010. JAMA 308(15):1545-54 (2012). (ICOSAPENT_DFNDT00020631-40)
1/8/2020		1634		Expert Report of Stephen G. Kunin with Exhibits A-D
1/8/2020		1635		Interview Agenda, Applicant Initiated Interview Summary, Response to Non-

Date Marked	Date Admitted	Number	Witness	Description
				Final Office Action Dated March 2, 2012 U.S. Patent Application No. 12/702,889. (AMRN03059780-814)
1/8/2020		1636		Response to Non-Final Action Dated April 4, 2012, U.S. Patent Application No. 13/349,153. (AMRN00212303-389)
1/8/2020		1637		Declaration of Philip Lavin Under 37 C.F.R. §1.132, U.S. Patent Application No. 12/702,889. (AMRN03059338-58)
1/8/2020		1638		Curriculum Vitae, Dr. R. Preston Mason (AMRN-PEXP-0000546-569)
1/8/2020		1639		Opening Expert Report of R. Preston Mason, Ph.D. with Appendix A and Exhibits A-B
1/8/2020		1640		Reply Expert Report of R. Preston Mason, Ph.D. with Exhibit A
1/8/2020		1641		Bhatt, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 380(1):11-22 (January 3, 2019) (AMRN-PEXP-0000689-700)
1/8/2020		1642		Mason and Jacob, Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochemica et Biophysical Acta 1848:502-509 (2015).

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1643		Mason and Jacob, Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism, version with track changes.(AMRN01366206-34)
1/8/2020		1644		Email between Stirtan and Mason re RP Mason Draft manuscript: EPA vs. DHA and TG-lowering agents (antioxidation, Cholesterol Domains) – AMRN comments (AMRN01366205)
1/8/2020		1645		Mason, et al. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochemica et Biophysical Acta 1858:3131-3140 (2016). (AMRN03146567-76)
1/8/2020		1646		Mason, et al. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomedicine & Pharmacotherapy 103:1231-1237 (2018). (AMRN-PEXP-0000539-45)
1/8/2020		1647		Email between Mason and Rowe re CDA (AMRN02187308-9)
1/8/2020		1648		Amarin Confidentiality Agreement (AMRN03171738-40)
1/8/2020		1649		Self-Medlin, et al. Glucose promotes membrane cholesterol crystalline

Date Marked	Date Admitted	Number	Witness	Description
				domain formation by lipid peroxidation. Biochimica et Biophysica Acta xxx:xxx-xxx (2009) (AMRN02187310-15)
1/8/2020		1650		Email between Mason and Rowe re agreement (AMRN02187316)
1/8/2020		1651		Email between Soni, Rowe, Stirtan, Grandolfi, Manku, and Doogan re Amarin 2009 Project Protocol (AMRN01636840-41)
1/8/2020		1652		Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Lipid Peroxidation and Membrane Structural Organization (AMRN02188384-88)
1/8/2020		1653		Email between Rowe and Mason re JELIS studies(AMRN00769425)
1/8/2020		1654		Email between Bress and Stirtan re Preston Mason Work-Order: For sign-off (AMRN00799606)
1/8/2020		1655		Mason and Jacob Research proposal: Comparative Effects of Eicosapentaenoic Acid (EPA), Docosahexanoic Acid (DHA), Fenofibrate, Niacin, Gemfibrozil – Alone or in Combination with Atorvastatin Metabolite – on Human Endothelial Function Following Exposure to oxLDL (AMRN00799607)
1/8/2020		1656		Email between Ketchum and Thero re Preston Mason: Important publication

Date Marked	Date Admitted	Number	Witness	Description
				development that involves add'l funding (AMRN01434884-88)
1/8/2020		1657		Email between Mason and Stirtan re ACC-Meeting with Preston Mason (2 pm Sat, Hyatt at Convention Center) (AMRN02915248-54)
1/8/2020		1658		Email between Mason and Stirtan re ACC-Meeting with Preston Mason (2 pm Sat, Hyatt at Convention Center) (AMRN00389762-64)
1/8/2020		1659		Mason, EPA Enhanced Nitric Oxide Bioavailability: Potential Synergistic Actions with Statins. (AMRN00389765-86)
1/8/2020		1660		Services Agreement (AMRN003171846-48)
1/8/2020		1661		Services Agreement (AMRN003171757-59)
1/8/2020		1662		Services Agreement (AMRN003171752-56)
1/8/2020		1663		Services Agreement (AMRN003171732-34)
1/8/2020		1664		Services Agreement (AMRN003171791-95)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1665		Consultancy Agreement (AMRN003171743-51)
1/8/2020		1666		Facsimile from Mason to Mandura attaching W-9 and Consultancy Agreement(AMRN003171796-804)
1/8/2020		1667		Getler, No Compliments for 'Supplements'. <a href="https://www.pbs.org/publiceditor/blogs/lombudsman/2016/02/04/no-compliments-for-supplements/">https://www.pbs.org/publiceditor/blogs/lombudsman/2016/02/04/no-compliments-for-supplements/</a> last accessed June 13, 2019
1/8/2020		1668		Mason, et al. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochemical and Biophysical Research Communications 483:425-429 (2017).
1/8/2020		1669		Email between Soni, Stirtan, and Braeckman re Follow up from AHA on human endothelial function and nitric oxide studies – [From Preston Mason – Confidential] (AMRN002752198-2210)
1/8/2020		1670		U.S. Patent Application Publication 2014/0249225 A1
1/8/2020		1671		U.S. Patent 10,172,818 B2



Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1672		Email between Mason and Stirtan re Summary of New Findings with EPA with attachment (AMRN002305585-86)
1/8/2020		1673		Rebuttal Expert Report of Peter R. Mathers on Non-Infringement of the Asserted Claims of the Patents-in-Suit
1/8/2020		1674		Materials Considered in Rebuttal Expert Report of Peter R. Mathers on Non-Infringement of the Asserted Claims of the Patents-In-Suit
1/8/2020		1675		Peter R. Mathers Bio
1/8/2020		1676		Final Printed Carton and Container Labels for approved NDA 202057/S-019 (AMRN03132168-77)
1/8/2020		1677		FDA, Distributing Scientific and Medical Publications on Unapproved and New Uses— Recommend Practices: Guidance for Industry (2014) (“FDA Unapproved Use Guidance”) (ICOSAPENT_DFNDT00018232-51)
1/8/2020		1678		Guidance for Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products – Content and Format(AMRN-PEXP-0010229-241)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1679		Lovenox label (ICOSAPENT_DFNDT00015711-51)
1/8/2020		1680		Eliquis® Label (AMRN-PEXP-0009835-79)
1/8/2020		1681		FDA, Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products —Content and Format: Guidance for Industry, at 10 (2018) (“FDA Labeling Guidance”) (AMRN-PEXP-0010242-261)
1/8/2020		1682		Guidance for Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products – Content and Format (AMRN-PEXP-0010187)
1/8/2020		1683		Expert Report of Sean Nicholson with Appendices A-E and Exhibits 1-31B
1/8/2020		1684		Reply Expert Report of Sean Nicholson with Appendices A-D and Exhibits 1-6
1/8/2020		1685		Beatty, Joel, and Shawn M Egan, “Amarin Corp (AMRN) 2019 Revenue Guidance Lower Than Expectations, TP \$20 (-\$8),” Citi Research (AMRN-PEXP-0007707-17)
1/8/2020		1686		Berndt, The U.S. Pharmaceutical Industry: Why Major Growth In Times

Date Marked	Date Admitted	Number	Witness	Description
				of Cost Containment? Health Affairs 20(2):100-114 (Mar/Apr 2001) (AMRN-PEXP-0002182-96)
1/8/2020		1687		Berndt, et al. Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market. The American Economic Review 85(2): 100-105 (May 1995) (AMRN-PEXP-0002272-78)
1/8/2020		1688		Cutler and McClellan, Is Technological Change in Medicine Worth? Health Affairs 20(5): 11-29 (Sept/Oct 2001)(AMRN-PEXP-0002402-20)
1/8/2020		1689		Reply Expert Report of Carl C. Peck, M.D.
1/8/2020		1690		Carl C. Peck, M.D. Prior Testimony
1/8/2020		1691		Materials Considered by C. Peck, M.D., June 10, 2019 Reply Expert Report
1/8/2020		1692		Curriculum Vitae, Carl C. Peck, M.D., Dr. h.c. (Uppsala)
1/8/2020		1693		21 C.F.R. §201.57 (ICOSAPENT_DFNDT00018074-94)
1/8/2020		1694		Clinical Study Report: A Phase 3, Multi-center, Placebo-Controlled,

Date Marked	Date Admitted	Number	Witness	Description
				Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglyceride Levels ?500 mg/dL and ?2000 mg/dL: The AMR101 MARINE Study. Results of the Double-Blind Treatment Period. Final Version. (AMRN00053457-54134)
1/8/2020		1695		Guidance for Industry, Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products – Content and Format (ICOSAPENT_DFNDT00018207-31)
1/8/2020		1696		Vascepa advertisement, “Vascepa looks different because it is different.” (AMRN03149773-4)
1/8/2020		1697		Rebuttal Expert Report of Jonathan I. Sheinberg, M.D., F.A.C.C., on Noninfringement of the Asserted Claims of the Patents-in-Suit with Exhibits A-B
1/8/2020		1698		Vascepa label (AMRN03132168-77)
1/8/2020		1699		Dr. Reddy’s Icosapent Ethyl Capsules, .5 gram ANDA 1.14.1.2 Annotated Draft Labeling Text (DRLEPA 0095591-647)
1/8/2020		1700		West-Ward Icosapent Ethyl Capsules label (WWICO-NV-002835-43 )
1/8/2020		1701		CDER Application Number 202057Orig1s000 Medical Review(s)

Date Marked	Date Admitted	Number	Witness	Description
				(ICOSAPENT_DFNDT00015424-567)
1/8/2020		1702		Lovenox label (ICOSAPENT_DFNDT00015711-51)
1/8/2020		1703		Eliquis® label (AMRN-PEXP-0009062-9106)
1/8/2020		1704		Opening Expert Report of Peter Paul Toth, M.D., Ph.D. with Exhibits A-C
1/8/2020		1705		Responsive Expert Report of Peter Toth, M.D., Ph.D. with Exhibits A-B
1/8/2020		1706		Reply Expert Report of Peter Toth, M.D., Ph.D. with Exhibit A
1/8/2020		1707		Mahley and Bersot, Drug Therapy for Hypercholesterolemia and Dyslipidemia. Chapter 36 in Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, 10th Ed. (2001). (AMRN00290358-92)
1/8/2020		1708		Toth, et al. Clinical and economic outcomes in a real-world population of patients with elevated triglyceride levels. Atherosclerosis 237:790-797 (2014).
1/8/2020		1709		Transcript of Hypertriglyceridemia: Managing Triglycerides to Reduce

Date Marked	Date Admitted	Number	Witness	Description
				Cardiovascular Risk. <a href="https://www.medscape.org/viewarticle/839217_transcript">https://www.medscape.org/viewarticle/839217_transcript</a> , last accessed 06/30/2019.
1/8/2020		1710		Toth, et al. Drug Therapy for Hypertriglyceridemia: Fibrates and Omega-3 Fatty Acids. Curr Atheroscler Rep. 11(1):71-79 (Jan. 2009).
1/8/2020		1711		Consultancy Agreement (AMRN03171927-37)
1/8/2020		1712		Consultancy Agreement (AMRN03171938-46)
1/8/2020		1713		Consultancy Agreement (AMRN03171947-54)
1/8/2020		1714		Consultancy Agreement (AMRN03171955-62)
1/8/2020		1715		Consultancy Agreement(AMRN03171963-73)
1/8/2020		1716		Consultancy Agreement (AMRN03171974-84)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1717		Services Agreement (AMRN03171985-89)
1/8/2020		1718		Services Agreement (AMRN03171990-92)
1/8/2020		1719		Services Agreement (AMRN03171993-95)
1/8/2020		1720		Speaker Program Metrics & Utilization as of June 27, 2013 (AMRN02386752-54)
1/8/2020		1721		ProPublica Dollars for Docs, Peter Toth, 2013 Payment Breakdown, <a href="https://projects.propublica.org/docdollars/doctors/pid/266019">https://projects.propublica.org/docdollars/doctors/pid/266019</a> , last accessed 06/24/2019
1/8/2020		1722		ProPublica Dollars for Docs, Peter Toth, 2014 Payment Breakdown, <a href="https://projects.propublica.org/docdollars/doctors/pid/266019">https://projects.propublica.org/docdollars/doctors/pid/266019</a> , last accessed 06/24/2019
1/8/2020		1723		ProPublica Dollars for Docs, Peter Toth, 2015 Payment Breakdown, <a href="https://projects.propublica.org/docdollars/doctors/pid/266019">https://projects.propublica.org/docdollars/doctors/pid/266019</a> , last accessed 06/24/2019
1/8/2020		1724		ProPublica Dollars for Docs, Peter Toth, 2016 Payment Breakdown, <a href="https://projects.propublica.org/docdollars/doctors/pid/266019">https://projects.propublica.org/docdollars/doctors/pid/266019</a> , last accessed 06/24/2019

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1725		Email between Toth and Everett re Ad-Board Follow Up (AMRN00305102-105)
1/8/2020		1726		Graham, 25 top-earning doctors in Illinois. <a href="https://www.chicagotribune.com/lifestyles/health/chi-na-docdollars-profiles-sidebar-htmlstory.html">https://www.chicagotribune.com/lifestyles/health/chi-na-docdollars-profiles-sidebar-htmlstory.html</a> , last accessed 06/24/2019.
1/8/2020		1727		Giuliani, Local doctor is in ... the money. <a href="http://www.saukvalley.com/2014/04/08/local-doctor-is-in-the-money/acz259h/?xsl=/pri.nl.xsl">www.saukvalley.com/2014/04/08/local-doctor-is-in-the-money/acz259h/?xsl=/pri.nl.xsl</a> , last accessed 06/25/2019
1/8/2020		1728		Subpoena to Testify at a Deposition in a Civil Action directed to Harold E. Bays
1/8/2020		1729		Harold E. Bays 2018 Curriculum Vitae (HB-AMRN00000001-7)
1/8/2020		1730		Statement of Investigator with Harold Bays 2009 Curriculum Vitae (AMRN00009725-32)
1/8/2020		1731		Native Spreadsheet: Amarin Corp. Consultant Spend 2009-2011 (AMRN03022105)
1/8/2020		1732		Email between Elson and Ketchum re Ad Comm estimated expenses with



Date Marked	Date Admitted	Number	Witness	Description
				attached spreadsheet (AMRN01493345-6)
1/8/2020		1733		Email between Bays and Soni re Invitation to Attend Amarin Expert Panel Meeting in Boston, USA (AMRN01502780-2)
1/8/2020		1734		Email between Crutchley and Bays re Dr. Bays – Honorarium for Amarin Expert Panel Meeting in Boston (AMRN01635508)
1/8/2020		1735		Email between Crutchley, Soni, Wicker, Osterloh, and Manku re Status Update Amarin Expert Panel Meeting – December 11-12 (AMRN01519654-5)
1/8/2020		1736		Group Exhibit:1) Bays, Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for Hypertriglyceridemia: A Primer for Clinicians. Drugs of Today 44(3): 205-246 (2008);2) Lovaza Label;3) Yokoyama, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. The Lancet 369:1090-98 (March 31, 2007);4) Harris, The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr 87(suppl):1997S-2002S (2008);5) Davidson, et al. Efficacy and Tolerability of Adding Prescription Omega-3 Fatty Acids 4 g/d to Simvastatin 40 mg/d in Hypertriglyceridemic Patients: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study. Clinical Therapeutics 29(7): 1354-1367 (July

Date Marked	Date Admitted	Number	Witness	Description
				2007). (ICOSAPENT_DFNDTS00007488-7529AMRN00598067AMRN00598068-76AMRN00598077-82AMRN00598083-96)
1/8/2020		1737		Tricor, in Physicians' Desk Reference 63 Ed. pp. 520-24 (2009)
1/8/2020		1738		Email between Braeckman and Bays re MARINE manuscript (AMRN02273377)
1/8/2020		1739		Bays, et al: Eicosapentaenoic Acid Ethyl Ester (AMR101) Theraoy in Patients with Very High Triglyceride Levels: The MARINE Trial. (AMRN01062083-114)
1/8/2020		1740		Email between Bays and Braeckman re MARINE manuscript (AMRN02903388-9)
1/8/2020		1741		Bays, et al. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients with Very High Triglyceride Levels (from the Multi-center, Placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] Trial). Am J Cardiol 108:682-690 (2011). (AMRN00524816-24)
1/8/2020		1742		Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Application No. 12/702,889 (AMRN03058234-36)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1743		Draft of Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Application No. 12/702,889 (AMRN02056723-25)
1/8/2020		1744		Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Patent Application No. 12/702,889 (AMRN03059316-37)
1/8/2020		1745		Non-Final Rejection, Patent Application No. 12/702,889 (AMRN03059251-72)
1/8/2020		1746		Response to Non-Final Office Action Dated November 4, 2011, Patent Application No. 12/702,889 (AMRN03059282-315)
1/8/2020		1747		Bays, Clinical Overview of Omacor: A Concentrated Formulation of Omega-3 Polyunsaturated Fatty Acids. AM J Cardiol 98(Suppl):71i-76i (2006). (ICOSAPENT_DFNDTS00007482-87.)
1/8/2020		1748		Declaration III of Harold E. Bays Under 37 C.F.R. § 1.132, U.S. Patent Application No. 12/702,889. (AMRN03059815-29)
1/8/2020		1749		Response to Non-Final Office Action Dated March 2, 2012, Patent Application No. 12/702,889 (AMRN03059789-814)
1/8/2020		1750		Declaration of Harold E. Bays Under 37 C.F.R. § 1.132, Patent Application

Date Marked	Date Admitted	Number	Witness	Description
				No. 13/458,496 (AMRN03030162-71)
1/8/2020		1751		Aaron Berg Linkedin profile, <a href="https://www.linkedin.com/in/aaron-berg-7b13033/">https://www.linkedin.com/in/aaron-berg-7b13033/</a> last accessed 8/25/2018
1/8/2020		1752		Amarin AMR101 in Hypertriglyceridemia, Non-confidential presentation (AMRN02165596-618 )
1/8/2020		1753		Email between Shalaby, Thero, and Berg re Notes (AMRN00826821)
1/8/2020		1754		Email between Berg, Padmanabhan, Boothe, and Boatman re Need more EPA feedback for JZs update for tomorrow, Send tonight? (AMRN02336076-78)
1/8/2020		1755		Email between Berg and Gilhooly re Central Files – Please look at (AMRN00893179)
1/8/2020		1756		Presentation: Why Approve Now_WN (AMRN01493374-80)
1/8/2020		1757		Email between Sedlack and Berg re off label (AMRN00820445)
1/8/2020		1758		Email between Thero and Berg, re E Brinton attempts to set the record

Date Marked	Date Admitted	Number	Witness	Description
				straight – we need to discuss proactively having docs (at least steering committee members) appropriately media trained. (AMRN00828482)
1/8/2020		1759		Email between Berg, Bashe, Kuhl, and Jones re basf president interview re 03 (AMRN02344161-2)
1/8/2020		1760		Email between Berg, Bashe, and Kuhl re Market Research/supplement use (AMRN-02344006-7)
1/8/2020		1761		Email between Gilhooly, Berg, Mayes, Delacluyse, Sharp-Stenken, and Beck re Teva WAC and attaching Vascepa Net Price gen Lovaza slide
1/8/2020		1762		Email forward from Berg to Thero re generic Lovaza – perception versus reality
1/8/2020		1763		GSK Reduction in Lovaza Direct Selling Effort Leads to Lower Rx Volume (AMRN02160507)
1/8/2020		1764		Email between Bashe and Berg re Why Merck's Niacin Failure Will Scare Drug Researchers(AMRN00829792-96)
1/8/2020		1765		Email between Berg and Rigo re Market (AMRN00842379-81)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1766		Email between Gilhooly and Ameres re Generic WAC Price Communication
1/8/2020		1767		Email between Gilhooly, Berg, Galdo, Ameres, and Beck re some help
1/8/2020		1768		Email between Berg and Bashe re Tomorrow (AMRN02344070-1)
1/8/2020		1769		plot diagrams titled Sales Volume – Japan and Icosapent Unit Volume – Japan
1/8/2020		1770		Email between Berg and Kuhl re guidelines and OM-3 use (AMRN02344042-44)
1/8/2020		1771		Vascepa Celebrity Campaign (AMRN00303084)
1/8/2020		1772		Vascepa Celebrity Brand Campaign (AMRN02352366)
1/8/2020		1773		Amarin Commercial Update (AMRN00859728-74)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1774		Email between Berg and Thero re Amarin Potential News Later Today (AMRN02376107-9)
1/8/2020		1775		Email between Berg and Bashe re Kowa deal (AMRN02376664-5)
1/8/2020		1776		Amarin Sales and Marketing Update
1/8/2020		1777		Spreadsheet: Amarin Corporation 2013-14 Budget, Marketing
1/8/2020		1778		U.S. Patent 7,022,713
1/8/2020		1779		Elephant Analytics, Amarin: How The Co-Promotion Agreement With Kowa Affects Required Sales Targets. <a href="https://seekingalpha.com/article/2119273-amarin-how-the-co-promotion-agreement-with-kowa-affects-required-sales-targets">https://seekingalpha.com/article/2119273-amarin-how-the-co-promotion-agreement-with-kowa-affects-required-sales-targets</a> , last accessed 07/24/2018
1/8/2020		1780		Email between Steier, Berg, Gilhooly, and Bruno re FYI – Amrin Media Coverage – Wednesday PM(AMRN00870842)
1/8/2020		1781		Native Spreadsheet re sales and price data Q1 2013 – Q2 2018

Date Marked	Date Admitted	Number	Witness	Description
				(AMRN03163817)
1/8/2020		1782		Native Spreadsheet re Quarterly Information Operating Loss Detail, SG&A Detail, and Net Sales Detail Q1-13 to Q2-18 (AMRN03163818)
1/8/2020		1783		Native Spreadsheet re Quarterly Information Operating Loss Detail, SG&A Detail, and Net Sales Detail Q1-13 to Q3-17 (AMRN03151451)
1/8/2020		1784		Native Spreadsheet re Quarterly Information Operating Loss Detail, SG&A Detail, and Net Sales Detail Q1-13 to Q2-17 (AMRN03151452)
1/8/2020		1785		Defendants' Joint Notice of Rule 30(b)(6) Deposition of Plaintiffs
1/8/2020		1786		Email between Park, Clement, and Others re Amarin Pharma Inc. et al. v. Hikma Pharmaceuticals USA Inc. et al., 16-cv-2525
1/8/2020		1787		Summary of 2013 and 2014 Commercial Spends and Vendors (excluding staffing) (AMRN00842922)
1/8/2020		1788		Vascepa marketing material



Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1789		KOL Expertise, Question and Answer (AMRN01493356-60)
1/8/2020		1790		Defendants' Joint Notice of Rule 30(b)(6) Deposition of Plaintiffs
1/8/2020		1791		Memorandum from Boal to Stewart re Idis Proposal for "Names Patient Sales" of Miraxion. (AMRN02099244-48)
1/8/2020		1792		Peet, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research 49:243-251 (2001). (AMRN01650526-34)
1/8/2020		1793		Email between Sedlack, Cooke, Cunningham, and Holmes re Minutes and Slides from EPA Triglycerides meeting – Thursday 20th December 2007 with attachments (AMRN02129382-413)
1/8/2020		1794		Email between Osterloh, Doogan, Wood, Cooke, Cunningham, Boal, and Shilling re EPA Hypertriglyceridemia Project Status and Investor Due Diligence with attachment (AMRN01671916-33)
1/8/2020		1795		EPA for Hypertriglyceridemia: Project Summary December 17, 2017 (AMRN02263071-74)
1/8/2020		1796		Email between Doogan, Manku, Osterloh, Cooke, and Lynch re Omacor

Date Marked	Date Admitted	Number	Witness	Description
				(Omega-3-Acid Ethyl Esters) – Current Clinical Trials (AMRN01672057-58)
1/8/2020		1797		Email between Manku, Cooke, Cunningham, and Lynch re EPA reduces cholesterol absorption from GIT tract and inhibits its synthesis in liver, attaching Mizuguchi 1992 article (AMRN01688512-9)
1/8/2020		1798		Cosgrove, AMR101 Takes on Lovaza: Amarin enters final phase of testing for its promising fish oil medication for high cholesterol. Rodman publishing 2010. (AMRN02113623-4)
1/8/2020		1799		Email between Soni and Aralihalli attaching Saito 2008 article. (AMRN00624045-51)
1/8/2020		1800		Amarin Next Generation Lipid Modification in Cardiovascular Disease: Investor Presentation (AMRN01171835-59)
1/8/2020		1801		Peet and Horrobin, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 36:7-18 (2002). (AMRN00731202-13)
1/8/2020		1802		Email between Manku, Cunningham, Holmes, and Cooke re Japanese publications – translations (AMRN01688238)
1/8/2020		1803		Email between Doogan, Rogan, and others re Investor Feedback attaching

Date Marked	Date Admitted	Number	Witness	Description
				spreadsheet (AMRN01566346-7)
1/8/2020		1804		Email between Crutchley, Bays, mcricqui@ucsd.edu, and Hawkins re CONFIDENTIAL: Amarin Expert Panel Meeting for AMR-101 (ethyl- EPA) Meeting Package with attachments (AMRN00597991-8096)
1/8/2020		1805		Email between Philip and Ketchum re Exec Summary RCM Series with attachment (AMRN01451526-639)
1/8/2020		1806		Kris-Etherton, et al. Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Circulation 106:2747-2757 (2002).
1/8/2020		1807		Plaintiffs' Initial Disclosures
1/8/2020		1808		Steve Ketchum Linkedin profile
1/8/2020		1809		Defendants' Joint Notice of Rule 30(b)(6) Deposition of Plaintiffs
1/8/2020		1810		Amarin AMR101 (icosapent ethyl) Capsules Investigator's Brochure Ed. 6.0 (AMRN03163819-937)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1811		Explanation of Changes Document AMR101, AMR101 Investigator's Brochure Version 6 (AMRN03163938-9)
1/8/2020		1812		Amarin Corporation PLC SEC Form 20-F
1/8/2020		1813		Presentation titled Amarin Ethyl EPA Hypertriglyceridemia Project Meeting (AMRN01224085-105)
1/8/2020		1814		Ethyl-EPA for Hypertriglyceridemia: Rationale and Outline of Proposed Development Program (AMRN00731672-682)
1/8/2020		1815		Email between Trefny and Stirtan attaching Lovaza label Dec2010 Tracked Changes (AMRN0786849-860)
1/8/2020		1816		P-IND 102,457, AMR101 Type B Meeting Information Package (AMRN02973472-592)
1/8/2020		1817		Amarin Corp PLC\UK Form 10-K Annual Report (ICOSAPENT_DFNDTS00003384-3403)
1/8/2020		1818		P-IND 102,457 AMR101 Request for Special Protocol Assessment: Phase 3 Study and final protocol AMR-01-01-0016(AMRN03019033-115)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1819		Email between Philip and Juliano attaching FDA EMDAC Amarin indication Brinton slides 10-16-31.1 (AMRN02714826-57)
1/8/2020		1820		Email between Philip and Ketchum re Exec Summary RCM Series (AMRN01451526-28)
1/8/2020		1821		Email between Philip and Ketchum re Regional Consultant Meetings Summaries (AMRN01451529)
1/8/2020		1822		Email between Sedlack, Kalinowski, Grandolfi, and Manku re Mochida selling API (AMRN01683571-72)
1/8/2020		1823		Email between Grandlofi and Soni attaching AMR101 vs. Epadel Chromalograms (Primera data).ppt (AMRN01535416-20)
1/8/2020		1824		Memorandum of Pre-IND Meeting Minutes (AMRN03107357-72)
1/8/2020		1825		Email between Bashe and Ketchum attaching Scientific Statement Against FDA Rescission of SPA for Vascepa (IPE) (AMRN02716805-21)
1/8/2020		1826		Email between Philip, Berg, and Thero re phone call dates/times attaching Brinton letter to FDA Commissioner (AMRN02343575-80)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1827		Email between Schultz and Soni re 3pm showing in New London, attaching Amarin Investor Presentation (AMRN01573009-38)
1/8/2020		1828		Amarin Next Generation Lipid Modification in Cardiovascular Disease: Investor Presentation
1/8/2020		1829		Amarin Cardioprotective Effects of Omega-3 Fatty Acids, AMR101 for Triglyceride Lowering (AMRN00731643)
1/8/2020		1830		Amarin Next Generation Lipid Modification in Cardiovascular Disease: Investor Presentation (AMRN01397826-57)
1/8/2020		1831		Rationale for Development of Ethyl-EPA for the Treatment of Hypertroglyceridemia (AMRN00204446-52)
1/8/2020		1832		Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease (AMRN03164813-5069)
1/8/2020		1833		Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic

Date Marked	Date Admitted	Number	Witness	Description
				Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial. Final v 1.0 (AMRN03167963-8515)
1/8/2020		1834		Amarin Efficacy Data, AMR-01-01-0019 (AMRN03169860-3170135)
1/8/2020		1835		Amarin Demographic Data, AMR-01-01-0019 (AMRN03168893-9177)
1/8/2020		1836		Letter to Dr. Rosenbraugh and Formal Dispute Resolution Project Manager re Formal Dispute Resolution Request, IND 103457 for Vascepa® (AMRN00111661-747)
1/8/2020		1837		Letter to Guettier re Formal Dispute Resolution Request, IND 103457 (S0077) (AMRN01478848)
1/8/2020		1838		Juliano and Ketchum, REDUCE-ITTM Presentation. (AMRN03156518-30)
1/8/2020		1839		Email between Ketchum, Juliano, Doyle, and Stirtan re mineral oil issue(AMRN01472289-90)
1/8/2020		1840		Email between Ketchum and Berry re Preps for Monday 2pm team call (AMRN01455752)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1841		Email between Ketchum and Berry re DMC Lipid Monitoring Guideline with attachments (AMRN02702785-90)
1/8/2020		1842		Email between Soni and Ballantyne re Placebo controls with AMR101 & Lovaza
1/8/2020		1843		Subpoena To Testify at a Deposition in a Civil Action directed to Philip Lavin (N/A)
1/8/2020		1844		Letter From K&L Gates To P. Lavin re Consulting Agreement With Respect To U.S. Patent Application Serial Number (AMRN03140245-46)
1/8/2020		1845		CV Philip T. Lavin (PL-AMRN000000001)
1/8/2020		1846		U.S. Patent 9,389,893 B2 (Stavros et al.) (N/A)
1/8/2020		1847		Daly, et al., "Enteral Nutrition With Supplemental Arginine, RNA, And Omega-3 Fatty Acids In Patients After Operation: Immunologic, Metabolic, And Clinical Outcome," (1992). (N/A)
1/8/2020		1848		American Statistical Association 1986 Proceedings Of Biopharmaceutical



Date Marked	Date Admitted	Number	Witness	Description
				Section (N/A)
1/8/2020		1849		Lavin, "Practical Considerations In The Coordination Of Clinical Trials," Clinical Trials Issues And Approaches (1983). (N/A)
1/8/2020		1850		Menon, et al., "Sample Size Calculation For Poisson Endpoint Using The Exact Distribution Of Difference Between Two Poisson Random Variables," (2011). (N/A)
1/8/2020		1851		Title Methods Of Treating Hypertriglyceridemia - 3717958/67(AMRN03024311)
1/8/2020		1852		Request For Continued Examination And Reponse To Office Action Dated August 18, 2011 (AMRN03025234-255)
1/8/2020		1853		Request for Type-B Meeting: Pre-IND Meeting (AMRN03105910-41)
1/8/2020		1854		Email between Manku, Cunningham, Holmes, and Cooke re Japanese publications – translations with attachments (AMRN01688238-360)
1/8/2020		1855		Email between Doogan, Manku, Osterloh, Cooke, and Lynch re Omacor

Date Marked	Date Admitted	Number	Witness	Description
				(Omega-3-Acid Ethyl Esters) – Current Clinical Trials (AMRN01672057-60)
1/8/2020		1856		Email between Manku, Cooke, Doogan, Lynch, and Osterloh re Meeting with Mochida's internal R and D team, attaching Satoh 2007 and Mizuguchi 1993 references (AMRN01688641-53)
1/8/2020		1857		Email between Manku, Cunningham, Holmes, and Cooke RE: (AMRN01688572-3)
1/8/2020		1858		Email between Crutchley, Sedlack, and others re Amarin Expert Panel Meeting for AMR-101 (ethyl-EPA) Meeting Package and attaching Amarin Expert Panel Meeting Materials (AMRN0588927-9018)
1/8/2020		1859		Presentation: Overview of Hypertriglyceridemia. AMR 101 Expert Panel Meeting, Boston (AMRN01574093-115)
1/8/2020		1860		Email between Osterloh, Braeckman, Soni, Doogan, Crutchley, and Manku re 12-Dec-2008 Expert Panel Meeting Comments on AMR101 Phase 3 Studies and attaching Ian's Notes from Amarin's Expert Panel Meeting 12th December 2008 (AMRN01531053-58)
1/8/2020		1861		Email from Manku to Cooke and Lynch re Final Slides for Boston attaching Boston Dec 12 08.ppt [Pleiotropic effects of EPA in Cardiovascular Diseases] (AMRN01688980-9008)
1/8/2020		1862		Email between Doogan, Sedlack, and others re Final Slides for Arisaph

Date Marked	Date Admitted	Number	Witness	Description
				attaching Partnering Presentation V6 July 31st.ppt (AMRN01673821-924)
1/8/2020		1863		Defendants' Notice of Deposition of Dr. Michael Miller
1/8/2020		1864		Declaration of Michael Miller, MD, FACC, FAHA, FNLA, FASPC on Claim Construction [Dkt. 89-1]
1/8/2020		1865		Materials Considered [Dkt. 89-4]
1/8/2020		1866		Reply Declaration of Michael Miller, MD, FACC, FAHA, FNLA, FASPC on Claim Construction [Dkt. 113-1]
1/8/2020		1867		Curriculum Vitae of Michael Miller [Dkt. 89-3]
1/8/2020		1868		Email between Soni and Miller re Amarin (AMRN03022275-6)
1/8/2020		1869		DRAFT NOTES, Meeting with Michael Miller – University of Maryland School of Medicine (AMRN01017280-1)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1870		Dr. Michael Miller's Consulting time for Amarin (Sept thru Dec, 2010) (AMRN02739796)
1/8/2020		1871		Dr. Michael Miller's Consulting time for Amarin (Jan thru June, 2011) (AMRN02769565)
1/8/2020		1872		2014 Clinical Development Department Goals – Status 2014 (AMRN03121925-31)
1/8/2020		1873		Dr. Michael Miller's Consulting time for Amarin (July thru December, 2011) (AMRN01077327)
1/8/2020		1874		Email between Soni and Schwarzkopf attaching spreadsheet: KOL Contacts – 19Nov2010 (AMRN01638777-8)
1/8/2020		1875		Email between Ketchum and Miller re Available to touch base this afternoon? (AMRN02702696)
1/8/2020		1876		Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106:3143-3421 (2002) (AMRN00289915-290194)
1/8/2020		1877		Exhibit 18 to Plaintiffs' Opening Markman Brief [Dkt. 89-20 to 86-26],

Date Marked	Date Admitted	Number	Witness	Description
				Excerpts from the File History of U.S. Patent No. 8,293,727
1/8/2020		1878		Jacobson, et al. Hypertriglyceridemia and Cardiovascular Risk Reduction, Clinical Therapeutics 29(5):763-777 (2007). (ICOSAPENT_DFNDTS00010211-25)
1/8/2020		1879		Exhibit 28 to Plaintiffs' Opening Markman Brief [Dkt. 89-37], C. Baigent et al., Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins, 366 LANCET 1267-78 (2005). (AMRN03130228-239)
1/8/2020		1880		Email between Doogan, Osterloh, and Cunningham re Test Message (AMRN01693774-6)
1/8/2020		1881		Amarin Portfolio Review Meeting (AMRN02105815-23)
1/8/2020		1882		Email between Osterloh, Doogan, Cunningham, and Cooke re CV strategy (AMRN01671955-59)
1/8/2020		1883		EPA for Hypertriglyceridemia, Minutes of project team meeting (AMRN02263119-22)
1/8/2020		1884		Email between Mallard, Cooke, Osterloh, Wood, Doogan, and Shilling

Date Marked	Date Admitted	Number	Witness	Description
				re Investor Calls and evidence to support EPA tg programme (AMRN02175481-2)
1/8/2020		1885		Email between Osterloh, Doogan, Wood, Cooke, Cunningham, Boal, and Shilling re EOA Hypertriglyceridemia Project Status and Investor Due Diligence attaching EPA Briefing Document (AMRN0167916-33)
1/8/2020		1886		Email between Osterloh and Wicker re Miraxion – US experts(PW-AMRN00000603-4)
1/8/2020		1887		Email between Osterloh and Wicker re Amarin – Confidential (PW-AMRN00000192-3)
1/8/2020		1888		Email between Osterloh, Morgan, and others re Agenda & EPA claim scenarios (PW-AMRN00001186-89)
1/8/2020		1889		Ian's Notes from Amarin's Expert Panel Meeting (AMRN01531055-58)
1/8/2020		1890		Hypertriglyceridemia Expert Panel Meeting (AMRN02088919-925)
1/8/2020		1891		Curriculum Vitae of Howard S. Weintraub (HW-AMRN00000001-11)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1892		Webpage: Howard Weintraub / NYU Langone Health, <a href="https://nyulangone.org/doctors/1457347767/howard-weintraub">https://nyulangone.org/doctors/1457347767/howard-weintraub</a> , last accessed
1/8/2020		1893		Consultancy Agreement (AMRN03115613-21)
1/8/2020		1894		Email between Soni and Weintraub RE: (AMRN01540795)
1/8/2020		1895		Dollars for Docs, Howard Weintraub. <a href="https://projects.propublica.org/docdollars/doctors/print/202475">https://projects.propublica.org/docdollars/doctors/print/202475</a> , last accessed
1/8/2020		1896		Email between Rowe and Weintraub re question (AMRN02900115-17)
1/8/2020		1897		Declaration of Howard Weintraub Under 37 C.F.R. § 1.132, Application No. 12/702,889 (AMRN03058275-83)
1/8/2020		1898		K&L Gates unexecuted Consulting Agreement with Respect to U.S. Patent Application Serial Number 12/702,889 (AMRN03140226-7)
1/8/2020		1899		Canaccord Genuity Expert Call: Amrn 101, Marine Trial Data. Edited Transcript (AMRN02844821-4849)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1900		Email between Rowe and Weintraub re Canaccord Genuity consultation request – Hypertriglyceridemia and AMR101 (AMRN00768524-25)
1/8/2020		1901		Email between Weintraub and Rowe re everything still ok for tomorrow at 5pm et? (AMRN02894016-20)
1/8/2020		1902		Weintraub, Update on marine omega-3 fatty acids: Management of dyslipidemia and current omega-3 treatment options. Atherosclerosis 230:381-389 (2013). (AMRN02325273-81)
1/8/2020		1903		Wei and Jacobson, Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis. Curr Atheroscler Rep 13:474-483 (2011).
1/8/2020		1904		Jacobson, et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. Journal of Clinical Lipidology 6:5-18 (2012). (AMRN00924808-21)
1/8/2020		1905		Applicant Initiated Interview Request Form, Application No. 12/702,889 (AMRN03058229-31)
1/8/2020		1906		Declaration of Howard Weintraub Under 37 C.F.R. §1.132 and Exhibits



Date Marked	Date Admitted	Number	Witness	Description
				(AMRN03059081-229)
1/8/2020		1907		Request for Continued Examination and Response to Office Action Dated August 18, 2011 (AMRN03059035-56)
1/8/2020		1908		Bays, et al. Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] Trial), Am J Cardiol 108:682-690 (2011) (AMRN00482295-303)
1/8/2020		1909		Tomoyuki, et al. Research Report: Efficacy and Safety of Ethyl Icosapentate (Epadel®) Given for a Long Term against Hyperlipidemia. Prog. Med. 21: 457-467 (2001). (AMRN02203920-46)
1/8/2020		1910		Weintraub Invoice for Consultative Services July-August 2013. (AMRN02709601-2)
1/8/2020		1911		Email between Doyle and Weintraub re Confidential: Vascepa Advisory Committee (AMRN02576725-6)
1/8/2020		1912		Email between Bress and Weintraub re Confidential: Vascepa Advisory Committee (AMRN02585990-4)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1913		Declaration of Ronald H. Wharton, M.D., in Support of Defendants' Claim Construction [Dkt. 102-1]
1/8/2020		1914		Curriculum Vitae, Ronald H. Wharton M.D. [Dkt. 102-4]
1/8/2020		1915		Materials Considered in Declaration of Ronald Wharton in Support of Defendants' Responsive Claim Construction Brief [Dkt. 102-3]
1/8/2020		1916		Exhibit 4 to Defendants' Responsive Claim Construction Brief [Dkt. 102-6], Calabresi et al., Omacor in Familial Combined Hyperlipidemia: Effects on Lipids and Low Density Lipoprotein Subclasses, Atherosclerosis 148:387-96 (2000)
1/8/2020		1917		Exhibit 5 to Defendants' Responsive Claim Construction Brief [Dkt. 102-7], Mori et. al., The Independent Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiovascular Risk Factors in Humans, Current Opinion Clinical Nutrition & Metabolic Care 9:95-104 (2006). (ICOSAPENT_DFNDTS00011016-25)
1/8/2020		1918		Exhibit 19 to Plaintiffs' Opening Markman Brief [Dkt. 89-27], Excerpts from the File History of U.S. Patent No. 8,293,728
1/8/2020		1919		Errata Sheet for the October 16, 23018 Transcript of Aaron Berg

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1920		Errata for the Deposition of Nicholas P. Godici, June 25, 2019
1/8/2020		1921		Errata Sheet for the June 19, 2019 Deposition Transcript of Ivan T. Hofmann
1/8/2020		1922		Errata Sheet for the Transcript of Rebecca Juliano, Ph.D.
1/8/2020		1923		Errata Sheet for the October 24, 2018 Transcript of Steven Ketchum, Ph.D.
1/8/2020		1924		Errata Sheet for the July 9, 2019 Transcript of John Kornak
1/8/2020		1925		Errata Sheet for the June 20, 2019 Transcript of Stephen Kunin
1/8/2020		1926		Errata Sheet for the September 21, 2018 Deposition of Philip T. Lavin
1/8/2020		1927		Errata Sheet for the June 27, 2019 Deposition of Peter Mathers

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1928		Errata Sheet for the February 15, 2018 Deposition of Michael Miller
1/8/2020		1929		Errata Sheet for the July 2, 2019 Deposition of Sean Nicholson
1/8/2020		1930		Errata Sheet for the July 2, 2019 Deposition of Jonathan I. Sheinberg
1/8/2020		1931		Errata Sheet for the September 14, 2018 Deposition of Howard S. Weintraub
1/8/2020		1932		Summary Minutes of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting (Oct. 16, 2013) (“Advisory Committee Minutes”) (AMRN01400429-33)
1/8/2020		1933		Agren et al., Fish Diet, Fish Oil and Docosahexaenoic Acid Rich Oil Lower Fasting and Postprandial Plasma Lipid Levels, 50 European J. Clinical Nutrition 765, 770 (1996) (“Agren”). (AMRN00289896—904)
1/8/2020		1934		Aung et al., Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks: Meta-Analysis of 10 Trials Involving 77,917 Individuals, 3 JAMA Cardiology 225 (2018). (AMRN03164724—32)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1935		Austin, Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond., Am J Epidemiol. 1989 Feb;129(2):249-59 (ICOSAPENT_DFNDT00016786-96)
1/8/2020		1936		21 C.F.R. § 312.22 (ICOSAPENT_DFNDT00018101-02)
1/8/2020		1937		21 C.F.R. § 314.3 (ICOSAPENT_DFNDT00018103-08)
1/8/2020		1938		21 U.S.C. § 355 (ICOSAPENT_DFNDT00018148-206)
1/8/2020		1939		35 U.S.C. §111
1/8/2020		1940		37 CFR §1.63
1/8/2020		1941		37 CFR §1.75
1/8/2020		1942		37 CFR 1.97

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1943		37 CFR 1.98
1/8/2020		1944		Manual of Patent Examining Procedure Eighth Edition, Revision No. 8
1/8/2020		1945		Manual of Patent Examining Procedure Eighth Edition, Revision No. 9
1/8/2020		1946		Bansal, et al., Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women, AMA. 2007 Jul 18;298(3):309-16 (ICOSAPENT_DFNDT00016285-ICOSAPENT_DFNDT00016292)
1/8/2020		1947		Buckley et al., Circulating Triacylglycerol and ApoE Levels in Response to EPA and Docosahexaenoic Acid Supplementation in Adult Human Subjects, 92 British J. Nutrition 477 (2004) ("Buckley"). (AMRN00290275-81)
1/8/2020		1948		Concin, et al., Mineral oil paraffins in human body fat and milk, 46(2) Food Chem Toxicol. 544-52, 551 (2008) ("Concin") (ICOSAPENT_DFNDT00016662-70)
1/8/2020		1949		Conquer et al., Supplementation with an Algae Source of Docosahexaenoic Acid Increases (n-3) Fatty Acid Status and Alters Selected Risk Factors for Heart Disease in Vegetarian Subjects, 126 J. Nutrition 3032 (1996) ("Conquer"). (AMRN00290326)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1950		Claim construction order in this case on August 10, 2018 Order (D.I. 135)
1/8/2020		1951		Joint Claim Construction Prehearing Statement Exhibit A: Constructions of the Claim Terms on which Parties Agree (D.I. 83-2, September 29, 2017).
1/8/2020		1952		Cucuzzella, Why should we treat high triglycerides?, J Fam Pract. 2004 February; 53(2):138-156 (ICOSAPENT_DFNDT00017638-49)
1/8/2020		1953		Amarin's Preliminary Validity Contentions
1/8/2020		1954		ECS/EAS Guidelines for the Management of Dyslipidemias, 32 Eur. Heart J. 1769–1818 (2011)
1/8/2020		1955		FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting (Oct. 16, 2013) (AMRN03106502-617)
1/8/2020		1956		Harris et al., Why do omega-3 fatty acids lower serum triglycerides?, 17 Curr. Opin. Lipidol. 387 (2006) (ICOSAPENT_DFNDT00018532-38)
1/8/2020		1957		Dean G. Karalis, A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids, 34 ADV. THER. 300-323 (2017)

Date Marked	Date Admitted	Number	Witness	Description
				(ICOSAPENT_DFNDT00016590-ICOSAPENT_DFNDT00016613)
1/8/2020		1958		Lembo et al., Chronic Constipation, 349 N. Eng. J. Med 1360-8, 1364 (2003)
				(ICOSAPENT_DFNDT00016150-ICOSAPENT_DFNDT00016158)
1/8/2020		1959		FDA, Approval Package NDA 21-654, Statistical Review (2004)
				(AMRN03059165-229)
1/8/2020		1960		Michael A. Miller, Disorders of Hypertriglyceridemia, in THE JOHNS HOPKINS TEXTBOOK OF DYSLIPIDEMIA 74 (Kwiterovich Jr. ed., 2009)
				(AMRN00291100-39)
1/8/2020		1961		Rambjør et al., Eicosapentaenoic Acid Is Primarily Responsible for Hypotriglyceridemic Effect of Fish Oil in Humans, 31 Lipids S-45 (1996)
				(ICOSAPENT_DFNDTS000006763-69)
1/8/2020		1962		REDUCE-IT Clinical Study Report (Feb. 27, 2019)
				(AMRN03168745)
1/8/2020		1963		Endocrine Society Releases Guidelines on Diagnosis and Management of Hypertriglyceridemia, 88(2) Am. Fam. Phys. 143-144 (July 2013)
1/8/2020		1964		Westerveld et al., Effects of Low-Dose EPA-E on Glycemic Control, Lipid Profile, Lipoprotein(a), Platelet Aggregation, Viscosity, and Platelet and Vessel Wall Interaction in NIDDM, 16 Diabetes Care 683, 686 (1993)



Date Marked	Date Admitted	Number	Witness	Description
				(AMRN-PEXP-0008415-22)
1/8/2020		1965		Classification of Hyperlipidaemias and Hyperlipoproteinaemias, Bulletin of the World Health Organization, 43(6): 891-915 (1970) (ICOSAPENT DFNDTS00007033-57)
1/8/2020		1966		Amarin Corp., Press Release, Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study (Mar. 28, 2019), available at <a href="https://investor.amarincorp.com/news-releases/news-release-details/amarin-submitssupplemental-new-drug-application-snda-us-fda">https://investor.amarincorp.com/news-releases/news-release-details/amarin-submitssupplemental-new-drug-application-snda-us-fda</a> . (ICOSAPENT DFNDT00015568-70)
1/8/2020		1967		Blacher et al., Cardiovascular Effects of B-Vitamins and/or n-3 Fatty Acids: the Su.Fol.Om3 Trial, 167 Int'l J. Cardiology 508 (2013) (AMRN03164797-802)
1/8/2020		1968		Bonds et al., Effect of Long-Chain $\omega$ -3 Fatty Acids and Lutein + Zeaxanthin Supplements on Cardiovascular Outcomes: Results of the Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial, 174 JAMA Internal Med. 763 (2014) (AMRN00862631-39)
1/8/2020		1969		Email between Riedell and Dist:Sales Professionals re Rapid Overview Webcast Presentation with attachment (AMRN00866721-45)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1970		Bosch et al., n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia, 367 N. Eng. J. Med. 309 (2012) (AMRN03147161–70)
1/8/2020		1971		Bowman et al., Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus, 379 N. Eng. J. Med. 1540 (2018)(AMRN-PEXP-0000701–11)
1/8/2020		1972		Center for Drug Evaluation and Research, Vascepa® Statistical Review (May 17, 2012), (AMRN00291613-89)
1/8/2020		1973		Cowan G. Statistical Data Analysis. Oxford University Press; 1998. (ICOSAPENT_DFNDT00019836-20045)
1/8/2020		1974		DRL Label (DRLEPA 0095595–96)
1/8/2020		1975		Einvik et al., A Randomized Clinical Trial on n-3 Polyunsaturated Fatty Acids Supplementation and All-Cause Mortality in Elderly Men at High Cardiovascular Risk, 17 Eur. J. Cardiovascular Prevention & Rehabilitation 588 (2010) (AMRN02642567–72)
1/8/2020		1976		Epanova® Label (AMRN03129984-94)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1977		Fosamax Label (ICOSAPENT_DFNDT00015688-710)
1/8/2020		1978		Goodman MS. Biostatistics for clinical and public health research. Milton Park, Abingdon, Oxon ; New York, NY: Routledge; 2018. (ICOSAPENT_DFNDT00019255-835)
1/8/2020		1979		H.R. Rep. No. 98-857, pt. I (1984), reprinted in 1984 U.S.C.C.A.N. 2647-48 (ICOSAPENT_DFNDT00018272-314)
1/8/2020		1980		FDA Adverse Events Reporting System (FAERS) Public Dashboard <a href="https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/8eef7d83-7945-4091-b349-e5c41ed49f99/state/analysis">https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/8eef7d83-7945-4091-b349-e5c41ed49f99/state/analysis</a> . (ICOSAPENT_DFNDT00018067)
1/8/2020		1981		Chapter 5: Atherosclerosis Lipoprotein Entry and Modification Contents, <a href="https://wrhhs.org/chapter-5-atherosclerosis/2/">https://wrhhs.org/chapter-5-atherosclerosis/2/</a> (ICOSAPENT_DFNDT00018371-81)
1/8/2020		1982		<a href="https://www.vascepa.com/high-triglycerides-cause">https://www.vascepa.com/high-triglycerides-cause</a> .(ICOSAPENT_DFNDT00018063-66)
1/8/2020		1983		Kromhout et al., n-3 Fatty Acids and Cardiovascular Events After

Date Marked	Date Admitted	Number	Witness	Description
				Myocardial Infarction, 363 N. Eng. J. Med. 2015 (2010) (AMRN01404742–01404753)
1/8/2020		1984		Lamisil® Label (ICOSAPENT_DFNDT00015617-629)
1/8/2020		1985		Levaquin® Label (ICOSAPENT_DFNDT00015630-687)
1/8/2020		1986		Lipitor Label (ICOSAPENT_DFNDT00015752-776)
1/8/2020		1987		Manson et al., Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer, 380 N. Eng. J. Med. 23 (2019) (AMRN-PEXP-0000712–721)
1/8/2020		1988		Marcello Pagano, Kimberlee Gauveau. Principles of biostatistics. Chapman and Hall/CRC; 2018 (ICOSAPENT_DFNDT00020046-630)
1/8/2020		1989		NDA No. 202057, FDA Approval Letter (July 26, 2012) (AMRN00482979-85)
1/8/2020		1990		Thomopoulous, Nick T. Thomopoulos. Probability distributions: with truncated, log and bivariate extensions (2018) (ICOSAPENT_DFNDT00019084-254)
1/8/2020		1991		Niacor® Label (AMRN-PEXP-0001667–72)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		1992		Oberman, et al., Chapter 4 Lipoprotein Transport, PRINCIPLES AND MANAGEMENT OF LIPID DISORDERS: A PRIMARY CARE APPROACH. PHARMACOLOGIC THERAPY OF LIPID DISORDERS. Williams and Wilkins, Baltimore; 87–105 (1992)
1/8/2020		1993		Omacor® Approval Letter (ICOSAPENT_DFNDTS00006366–68)
1/8/2020		1994		Omtryg® Label (AMRN03130027–41)
1/8/2020		1995		ORIGIN Trial Investigators, Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE), 39 Diabetes Care 709 (2016)(AMRN-PEXP-0001737–44)
1/8/2020		1996		Oxycontin Label (ICOSAPENT_DFNDT00015571-616)
1/8/2020		1997		Rauch et al., OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction, 122 Circulation 2152 (2010) (AMRN01521522–30)
1/8/2020		1998		Roncaglioni et al., n-3 Fatty Acids in Patients with Multiple Cardiovascular

Date Marked	Date Admitted	Number	Witness	Description
				Risk Factors, 368 N. Eng. J. Med. 1800 (2013) (AMRN03147275—83)
1/8/2020		1999		Saxenda® Label (ICOSAPENT_DFNDT00015828-839)
1/8/2020		2000		Tricor® 2018 Label (ICOSAPENT_DFNDT00015777-814)
1/8/2020		2001		U.S. Patent No. 10,278,936 (ICOSAPENT_DFNDT00017548-600)
1/8/2020		2002		Victoza® Label (ICOSAPENT_DFNDT00015815-827)
1/8/2020		2003		Vital News Volume 3, Issue 1 March 2017 (AMRN03147654-57)
1/8/2020		2004		Vittinghoff E, Glidden, David V., Shiboski, Stephen C., McCulloch, Charles E. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. 2nd ed. New York: Springer; 2012. 509 p. (Statistics for biology and health). (ICOSAPENT_DFNDT00018558-19083)
1/8/2020		2005		Zocor® (simvastatin) 2007 label (ICOSAPENT_DFNDT00018539-57)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2006		Complaint for Patent Infringement, Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Roxane Laboratories, Inc. and Hikma Pharmaceuticals PLC, Case No. 2:16-cv-02525, filed October 31, 2016
1/8/2020		2007		Answer, Affirmative Defenses, and Counterclaims, Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Roxane Laboratories, Inc. and Hikma Pharmaceuticals PLC, Case No. 2:16-cv-02525-MMD-NJK, filed January 9, 2017
1/8/2020		2008		Complaint for Patent Infringement, Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., Case No. 2:16-cv-2562, filed November 4, 2016
1/8/2020		2009		Answer, Affirmative Defenses, and Counterclaims of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Ltd., Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Limited v. Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., Case No.: 2:14-cv-02562 / 2:16-cv-02525 (Consolidated), filed January 13, 2017
1/8/2020		2010		Orange Book at <a href="https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=002&amp;Appl_No=202057&amp;Appl_type=N">https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=002&amp;Appl_No=202057&amp;Appl_type=N</a> , accessed April 22, 2019 (ICOSAPENT_DFNDT00016784-85)
1/8/2020		2011		Consolidation Order, filed November 7, 2017

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2012		<a href="https://www.news-medical.net/health/Hypertriglyceridemia-Cause-and-Symptoms.aspx">https://www.news-medical.net/health/Hypertriglyceridemia-Cause-and-Symptoms.aspx</a> , accessed April 29, 2019. (ICOSAPENT_DFNDT00016589)
1/8/2020		2013		<a href="https://www.jabfm.org/content/19/3/310">https://www.jabfm.org/content/19/3/310</a> , accessed April 16, 2019. (ICOSAPENT_DFNDT00016579-88)
1/8/2020		2014		Sweeney, Mary Ellen T., and Romesh Khardori, "Hypertriglyceridemia Medication," Medscape, available at <a href="https://emedicine.medscape.com/article/126568-medication">https://emedicine.medscape.com/article/126568-medication</a> (ICOSAPENT_DFNDT00018035-42)
1/8/2020		2015		<a href="https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statin-side-effects/art-20046013">https://www.mayoclinic.org/diseases-conditions/high-blood-cholesterol/in-depth/statin-side-effects/art-20046013</a> (ICOSAPENT_DFNDT00016813-16)
1/8/2020		2016		<a href="https://www.medicalnewstoday.com/articles/8274.php">https://www.medicalnewstoday.com/articles/8274.php</a> , accessed April 25, 2019. (ICOSAPENT_DFNDT00016817-20)
1/8/2020		2017		<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028601/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028601/</a> , accessed April 29, 2019. (ICOSAPENT_DFNDT00016834-43)
1/8/2020		2018		<a href="https://healthengine.com.au/info/fibrates">https://healthengine.com.au/info/fibrates</a> , accessed April 29, 2019. (ICOSAPENT_DFNDT00016314-15)
1/8/2020		2019		Lipofen® FDA Label, revised November 2018, see <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021612s017lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021612s017lbl.pdf</a> (ICOSAPENT_DFNDT00016614-21)



Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2020		<a href="https://medlineplus.gov/druginfo/meds/a601052.html">https://medlineplus.gov/druginfo/meds/a601052.html</a> , accessed May 9, 2019. (ICOSAPENT_DFNDT00016293-95)
1/8/2020		2021		<a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021656">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021656</a> (ICOSAPENT_DFNDT00016882-83)
1/8/2020		2022		<a href="http://tricortablets.com/">http://tricortablets.com/</a> , accessed April 29, 2019 (ICOSAPENT_DFNDT00016146-47)
1/8/2020		2023		Lipofen, Drugs@FDA: FDA Approved Drugs Products <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021612">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021612</a> , accessed April 23, 2019 (ICOSAPENT_DFNDT00016622-23)
1/8/2020		2024		Triglide® FDA Label, revised May 2018, see <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021350s0201bl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021350s0201bl.pdf</a> (ICOSAPENT_DFNDT00016884-900)
1/8/2020		2025		Triglide Drugs@FDA: FDA Approved Drugs Products <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021350">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021350</a> , accessed April 23, 2019 (ICOSAPENT_DFNDT00016901-02)
1/8/2020		2026		Antara® FDA Label, revised October 2018, see <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021695s0181bl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021695s0181bl.pdf</a> (ICOSAPENT_DFNDT00016121-39)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2027		Antara Website, <a href="http://www.antararx.com/">http://www.antararx.com/</a> , accessed April 23, 2019. (ICOSAPENT_DFNDT00016119-20)
1/8/2020		2028		Fenoglide® FDA Label, revised March 2019, see <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s009lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s009lbl.pdf</a> (ICOSAPENT_DFNDT00016296-311)
1/8/2020		2029		Trilipix® FDA Label, revised November 2018, see <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022224s014lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022224s014lbl.pdf</a> (ICOSAPENT_DFNDT00016908-27)
1/8/2020		2030		Trilipix Drugs@FDA: FDA Approved Drugs Products <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=022224">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=022224</a> (ICOSAPENT_DFNDT00016928-30)
1/8/2020		2031		Fibricor® FDA Label, revised May 2018, see <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022418s014lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022418s014lbl.pdf</a> (ICOSAPENT_DFNDT00016316-33)
1/8/2020		2032		Fibricor Drugs@FDA: FDA Drug Products <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=022418">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=022418</a> , accessed April 24, 2019. (ICOSAPENT_DFNDT00016334-35)
1/8/2020		2033		Lopid® FDA Label, revised April 2017, see <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018422s056lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018422s056lbl.pdf</a> (ICOSAPENT_DFNDT00016624-38)
1/8/2020		2034		LOPID, Drugs@FDA: FDA Approved Drugs

Date Marked	Date Admitted	Number	Witness	Description
				Products <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=018422">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=018422</a> , accessed April 24, 2019 (ICOSAPENT_DFNDT00016639-40)
1/8/2020		2035		Niaspan® FDA Label, revised February 2013, see <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020381s048lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020381s048lbl.pdf</a> (ICOSAPENT_DFNDT00016671-99)
1/8/2020		2036		Niaspan Drugs@FDA: FDA Approved Drugs Products <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=020381">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=020381</a> (ICOSAPENT_DFNDT00016700-03)
1/8/2020		2037		<a href="https://www.niaspan.com/what-is-niaspan">https://www.niaspan.com/what-is-niaspan</a> , accessed May 1, 2019. (ICOSAPENT_DFNDT00017635-37)
1/8/2020		2038		<a href="https://www.tevapharm.com/news/teva_announces_exclusive_launch_of_generic_niaspan_in_the_united_states_09_13.aspx">https://www.tevapharm.com/news/teva_announces_exclusive_launch_of_generic_niaspan_in_the_united_states_09_13.aspx</a> , accessed April 25, 2019 (ICOSAPENT_DFNDT00016830)
1/8/2020		2039		OH, Management of Hypertriglyceridemia, American Family Physician, <a href="https://www.aafp.org/afp/2007/0501/p1365.html">https://www.aafp.org/afp/2007/0501/p1365.html</a> (ICOSAPENT_DFNDT00016657-61)
1/8/2020		2040		McKenney, Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia, <a href="https://www.ncbi.nlm.nih.gov/pubmed/17461707">https://www.ncbi.nlm.nih.gov/pubmed/17461707</a> ; (ICOSAPENT_DFNDT00016812)
1/8/2020		2041		Moloudizargari, Effects of the polyunsaturated fatty acids, EPA and

Date Marked	Date Admitted	Number	Witness	Description
				DHA, on hematological malignancies: a systematic review <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837752/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837752/</a> , accessed May 8, 2019 (ICOSAPENT DFNDT00016235-247)
1/8/2020		2042		Lovasa Drugs@FDA: FDA Approved Drugs Products <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021654">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021654</a> , accessed April 29, 2019 (ICOSAPENT DFNDT00016644-560)
1/8/2020		2043		Reliant Pharmaceuticals, Inc., Pre-effective Amendment No. 3 to Form S-1 dated August 10, 2007 (AMRN-PEXP-0006773-7098)
1/8/2020		2044		Koski, Omega-3-acid Ethyl Esters (Lovaza) For Severe Hypertriglyceridemia. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683599/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683599/</a> , accessed April 17, 2019 (ICOSAPENT DFNDT00016704-10)
1/8/2020		2045		GSK to Acquire Reliant Pharmaceuticals for \$1.65B. <a href="https://www.genengnews.com/news/gsk-to-acquire-reliant-pharmaceuticals-for-1-65b/27018604/">https://www.genengnews.com/news/gsk-to-acquire-reliant-pharmaceuticals-for-1-65b/27018604/</a> (ICOSAPENT DFNDT00016526-27)
1/8/2020		2046		Teva Announces First Approval and Launch of Generic Lovaza® Capsules in the United States. <a href="https://www.tevapharm.com/news/teva_announces_first_approval_and_launch_of_generic_lovaza_capsules_in_the_united_states_04_14.aspx">https://www.tevapharm.com/news/teva_announces_first_approval_and_launch_of_generic_lovaza_capsules_in_the_united_states_04_14.aspx</a> , accessed April 30, 2019 (ICOSAPENT DFNDT00016831-33)
1/8/2020		2047		S.2748 - Drug Price Competition and Patent Term Restoration Act of 1984.

Date Marked	Date Admitted	Number	Witness	Description
				<a href="https://www.congress.gov/bill/98th-congress/senate-bill/2748">https://www.congress.gov/bill/98th-congress/senate-bill/2748</a> , accessed April 26, 2019 (ICOSAPENT_DFNDT00016821-22)
1/8/2020		2048		Coster, The Waxman-Hatch Generic Drug Law. <a href="https://www.uspharmacist.com/article/the-waxman-hatch-generic-drug-law">https://www.uspharmacist.com/article/the-waxman-hatch-generic-drug-law</a> , accessed April 26, 2019 (ICOSAPENT_DFNDT00016563-78)
1/8/2020		2049		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2013 (AMRN-PEXP-0005699-833)
1/8/2020		2050		Quarterly Financial Summary Q1 2013-Q4 2018(AMRN03171432)
1/8/2020		2051		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2012 (AMRN-PEXP-0005520-698)
1/8/2020		2052		Amarin Corporation plc, Second Quarter 2008 Earnings Call Transcript, <a href="https://seekingalpha.com/article/97385-amarin-corporation-plc-q2-2008-earningscall-transcript?part=single">https://seekingalpha.com/article/97385-amarin-corporation-plc-q2-2008-earningscall-transcript?part=single</a> , accessed April 17, 2019 (ICOSAPENT_DFNDT00015890-95)
1/8/2020		2053		The Pharmacy Times article, dated August 15, 2009, "The Hatch-Waxman Act – 25 Years Later: Keeping the Pharmaceutical Scales Balances," <a href="https://www.pharmacytimes.com/publications/supplement/2009/genericsupplement0809/generic-hatchwaxman-0809">https://www.pharmacytimes.com/publications/supplement/2009/genericsupplement0809/generic-hatchwaxman-0809</a> ,

Date Marked	Date Admitted	Number	Witness	Description
				accessed April 26, 2019 (ICOSAPENT_DFNDT00016548-62)
1/8/2020		2054		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2018 (AMRN-PEXP-0007482-685)
1/8/2020		2055		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2011 (AMRN-PEXP-0005304-519)
1/8/2020		2056		Amarin Presentation, “2017 Operating Plan,” (AMRN03151453-514)
1/8/2020		2057		Amarin Corporation plc, Fourth Quarter 2018 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/4244867-amarin-corporation-plc-amrn-ceo-john-thero-q4-2018-results-earningscall-transcript?part=single">https://seekingalpha.com/article/4244867-amarin-corporation-plc-amrn-ceo-john-thero-q4-2018-results-earningscall-transcript?part=single</a> , accessed April 17, 2019 (ICOSAPENT_DFNDT00015869-81)
1/8/2020		2058		Boris, John T., et al., “Lowering Sales on Slower Ramp & Execution Risk; Keener Focus on Shareholder Value Needed,” SunTrust Robinson Humphrey (AMRN-PEXP-0007737-47)
1/8/2020		2059		Chen, Louise et al., “Don’t Die of a Broken Heart; Physician Survey Shows How Vascepa Can Help,” Cantor Fitzgerald. (AMRN-PEXP-0007220-54)
1/8/2020		2060		Diabetes Patient Advocacy Coalition, “How the FDA Drug Approval Process

Date Marked	Date Admitted	Number	Witness	Description
				Works,” available at <a href="http://diabetespac.org/fda-drug-approval-process/">http://diabetespac.org/fda-drug-approval-process/</a> (AMRN-PEXP-0003460-65)
1/8/2020		2061		H.C. Wainwright & Co. Earnings Update, May 11, 2015 (ICOSAPENT_DFNDT00016540-47)
1/8/2020		2062		Fein, Andrew S., et al., “Embracing a Decidedly Non-Orphan Disease Company; Reit Buy and Raising PT to \$51,” H.C. Wainwright & Co. (AMRN-PEXP-0007718-22)
1/8/2020		2063		Chen, Louise et al., “If You Had Any Concerns Going Into 2019, REDUCE-IT,” Cantor Fitzgerald. (AMRN-PEXP-0007205-19)
1/8/2020		2064		Yee, Michael J. et al., “Easy and great tuck-in for pharma global salesforce,” Jefferies Research Services (AMRN-PEXP-0007725-35)
1/8/2020		2065		H.C. Wainwright & Co. Earnings Update, dated February 26, 2016 (ICOSAPENT_DFNDT00016528-34)
1/8/2020		2066		H.C. Wainwright & Co. Earnings Update, dated March 1, 2017 (ICOSAPENT_DFNDT00016535-39)
1/8/2020		2067		Amarin NDTI Jan 08 to Nov 12 010819.xlsx, (AMRN-PEXP-0007099)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2068		Complaint, Amarin Pharma, Inc. v. U.S. Food & Drug Admin., No. 1:15-cv-03588 (S.D.N.Y. May 7, 2015). (ICOSAPENT_DFNDT00016159-234)
1/8/2020		2069		Opinion & Order, Amarin Pharma, Inc. v. U.S. Food & Drug Admin., No. 1:15-cv-03588 (S.D.N.Y. Aug. 7, 2015) (ICOSAPENT_DFNDT00016711-81)
1/8/2020		2070		Amarin Corporation plc, Third Quarter 2015 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/3644706-amarins-amrn-ceo-john-thero-q3-2015-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/3644706-amarins-amrn-ceo-john-thero-q3-2015-results-earnings-calltranscript?part=single</a> , accessed May 6, 2019 (ICOSAPENT_DFNDT00016091-101)
1/8/2020		2071		Amarin Corporation plc, Form 10-Q, for the Quarter ended March 31, 2019, pg. 7, see <a href="https://www.sec.gov/Archives/edgar/data/897448/000156459019014555/amrn-10q_20190331.htm">https://www.sec.gov/Archives/edgar/data/897448/000156459019014555/amrn-10q_20190331.htm</a> , accessed May 3, 2019 (ICOSAPENT_DFNDT00015949-6021)
1/8/2020		2072		Amarin Corporation plc, First Quarter 2019 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/4258570-amarins-amrn-ceo-john-thero-q1-2019-results-earnings-calltranscript?part=single?part=single">https://seekingalpha.com/article/4258570-amarins-amrn-ceo-john-thero-q1-2019-results-earnings-calltranscript?part=single?part=single</a> , accessed May 3, 2019 (ICOSAPENT_DFNDT00016068-80)
1/8/2020		2073		Amarin Corporation plc, Fourth Quarter 2015 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/3931496-amarins-amrn-ceo-john-thero-q4-2015-results-earnings-">https://seekingalpha.com/article/3931496-amarins-amrn-ceo-john-thero-q4-2015-results-earnings-</a>



Date Marked	Date Admitted	Number	Witness	Description
				calltranscript?part=single, accessed April 29, 2019 (ICOSAPENT_DFNDT00016102-18)
1/8/2020		2074		Amarin Corporation plc, Presents at Cowen Health Care Conference, see <a href="https://seekingalpha.com/article/4248486-amarin-corporation-plc-amrn-presents-cowen-health-care-brokerconference-call-transcript?part=single">https://seekingalpha.com/article/4248486-amarin-corporation-plc-amrn-presents-cowen-health-care-brokerconference-call-transcript?part=single</a> , accessed May 7, 2019. (ICOSAPENT_DFNDT00015882-89)
1/8/2020		2075		GfK Presentation, "VASCEPA SFE, Q3 2017, Quantitative Research, Final Report Prepared for Amarin" September 1, 2017. (AMRN03152279-308)
1/8/2020		2076		PharmaSight Research Presentation, "Vascepa® New Promotional Campaign Exploration: Phase 1: Message Testing" (AMRN03152472-521)
1/8/2020		2077		AplusA Report, "Vascepa® (Icosapent ethyl), US Market Surveillance Study (ATU), Final Report of Findings," January 2016 v.2b (AMRN03151938-2047)
1/8/2020		2078		ZS Associates Presentation, "Vascepa Wave 2 PhysPulse Findings," (AMRN03151826-937)
1/8/2020		2079		Amarin Corporation plc, First Quarter 2014 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/2206783-amarins-amrn-ceo-john-thero-on-q1-2014-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/2206783-amarins-amrn-ceo-john-thero-on-q1-2014-results-earnings-calltranscript?part=single</a> , accessed April 17, 2019 (ICOSAPENT_DFNDT00016057-67)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2080		Amarin Corporation plc, Fourth Quarter 2012 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/1236761-amarin-corporations-ceo-discusses-q4-2012-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/1236761-amarin-corporations-ceo-discusses-q4-2012-results-earnings-calltranscript?part=single</a> , accessed April 18, 2019 (ICOSAPENT_DFNDT00015928-37)
1/8/2020		2081		Amarin, SEC Form 10-K for Fiscal Year Ended December 31, 2015 (AMRN-PEXP-0005984-6145)
1/8/2020		2082		Amarin Corporation plc, Third Quarter 2013 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/1820862-amarins-ceo-discusses-q3-2013-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/1820862-amarins-ceo-discusses-q3-2013-results-earnings-calltranscript?part=single</a> (ICOSAPENT_DFNDT00016043-56)
1/8/2020		2083		Amarin Fourth Quarter 2013 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/2057373-amarin-management-discusses-q4-2013-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/2057373-amarin-management-discusses-q4-2013-results-earnings-calltranscript?part=single</a> , accessed April 18, 2019 (ICOSAPENT_DFNDT00015938-48)
1/8/2020		2084		<a href="https://www.kowapharma.com/products/">https://www.kowapharma.com/products/</a> , accessed April 16, 2019 (ICOSAPENT_DFNDT00016797-811)
1/8/2020		2085		Amarin Corporation plc, First Quarter 2013 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/1421861-amarin-corporation-ceo-discusses-q1-2013-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/1421861-amarin-corporation-ceo-discusses-q1-2013-results-earnings-calltranscript?part=single</a> , accessed April 26, 2019

Date Marked	Date Admitted	Number	Witness	Description
				(ICOSAPENT_DFNDT00015856-68)
1/8/2020		2086		Amarin Corporation plc, Second Quarter 2014 Earnings Call Transcript, see
				<a href="https://seekingalpha.com/article/2404405-amarins-amrn-ceo-john-thero-on-q2-2014-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/2404405-amarins-amrn-ceo-john-thero-on-q2-2014-results-earnings-calltranscript?part=single</a> , accessed April 28, 2019 (ICOSAPENT_DFNDT00016081-90)
1/8/2020		2087		Amarin Corporation plc, First Quarter 2016 Earnings Call Transcript, see
				<a href="https://seekingalpha.com/article/3971859-amarin-corporations-amrn-ceo-john-thero-q1-2016-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/3971859-amarin-corporations-amrn-ceo-john-thero-q1-2016-results-earnings-calltranscript?part=single</a> , accessed April 23, 2019 (ICOSAPENT_DFNDT00015896-903)
1/8/2020		2088		Total Promotional Dollars.xlsx (AMRN-PEXP-0007105)
1/8/2020		2089		Amarin Corporation plc, Second Quarter 2013 Earnings Call Transcript, see
				<a href="https://seekingalpha.com/article/1621292-amarins-ceo-discusses-q2-2013-resultsearnings-call-transcript?part=single">https://seekingalpha.com/article/1621292-amarins-ceo-discusses-q2-2013-resultsearnings-call-transcript?part=single</a> , accessed April 29, 2019. (ICOSAPENT_DFNDT00016030-42)
1/8/2020		2090		Amarin Corporation plc, First Quarter 2017 Earnings Call Transcript, see
				<a href="https://seekingalpha.com/article/4068455-amarin-corporations-amrn-ceo-john-thero-q1-2017-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/4068455-amarin-corporations-amrn-ceo-john-thero-q1-2017-results-earnings-calltranscript?part=single</a> and
				<a href="https://www.vascepa.com/savings-program">https://www.vascepa.com/savings-program</a> , accessed April 5, 2019 (ICOSAPENT_DFNDT00015904-14)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2091		<a href="https://www.vascepa.com/savings-program">https://www.vascepa.com/savings-program</a> , accessed April 28, 2019 (ICOSAPENT_DFNDT00017601-11)
1/8/2020		2092		Amarin Corporation plc, Fourth Quarter 2016 Earnings Call Transcript, see <a href="https://seekingalpha.com/article/4050593-amarin-corporations-amrn-ceo-john-thero-q4-2016-results-earnings-calltranscript?part=single">https://seekingalpha.com/article/4050593-amarin-corporations-amrn-ceo-john-thero-q4-2016-results-earnings-calltranscript?</a> part=single, accessed April 29, 2019 (ICOSAPENT_DFNDT00015915-27)
1/8/2020		2093		Monthly Module Views- Sales (NSP)_1_Jan-02-2019.xlsx, (AMRN-PEXP-0007103)
1/8/2020		2094		Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Product Details for NDA 202057, Vascepa 500MG and Vascepa 1GM, <a href="https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&amp;Appl_No=202057">https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=N&amp;Appl_No=202057</a> , accessed April 22, 2019 (ICOSAPENT_DFNDT00016782-3)
1/8/2020		2095		Amarin Announces Market Introduction of Vascepa 01.24.2013, <a href="https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-market-introductionvascepar-icosapent-ethyl">https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-market-introductionvascepar-icosapent-ethyl</a> , accessed April 23, 2019. (ICOSAPENT_DFNDT00015853-55)
1/8/2020		2096		Amarin Pure EPA Vascepa Now Available 10.25.2016, <a href="https://investor.amarincorp.com/news-releases/news-release-details/pure-epavascepar-now-available-new-">https://investor.amarincorp.com/news-releases/news-release-details/pure-epavascepar-now-available-new-</a>

Date Marked	Date Admitted	Number	Witness	Description
				smaller-half-gram-capsule, accessed April 23, 2019. (ICOSAPENT_DFNDT00015850-52)
1/8/2020		2097		Antara-Drugs@FDA: FDA Approved Drug Products, <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021695">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=021695</a> (ICOSAPENT_DFNDT00016140-42)
1/8/2020		2098		Fenoglide, Drugs@FDA: FDA Drug Products, <a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=022118">https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=022118</a> , accessed April 24, 2019. (ICOSAPENT_DFNDT00016312-13)
1/8/2020		2099		Lovaza® FDA Label (revised 05/2014), see <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021654s041lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021654s041lbl.pdf</a>
1/8/2020		2100		<a href="https://www.gsk.com/media/2682/annual-report-2007.pdf">https://www.gsk.com/media/2682/annual-report-2007.pdf</a> (ICOSAPENT_DFNDTS00016342-525)
1/8/2020		2101		Bays, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev. Cardiovasc. Ther. 6(3): 391-409 (2008) (AMRN00206290-308)
1/8/2020		2102		Bays, et al. Rationale for Prescription Omega-3-Acid Ethyl Ester Therapy for Hypertriglyceridemia: A Primer for Clinicians. Drugs of Today 44(3): 205-246 (March 2008) (AMRN00290221-264)
1/8/2020		2103		High Cholesterol/Very High Triglycerides.

Date Marked	Date Admitted	Number	Witness	Description
				<a href="https://www.cardiosmart.org/Heart-Conditions/High-Cholesterol/High-Cholesterol-Home/Very-High-Triglycerides">https://www.cardiosmart.org/Heart-Conditions/High-Cholesterol/High-Cholesterol-Home/Very-High-Triglycerides</a> (AMRN-PEXP-0000366)
1/8/2020		2104		Amarin Pharma, Inc. Citizen Petition to FDA (AMRN03024268-80)
1/8/2020		2105		FDA Letter responding to Amarin Citizen Petition (AMRN01408774-784)
1/8/2020		2106		Transcript of Endocrinologic and Metabolic Drugs Advisory Committee Meeting, Oct. 16, 2013 (AMRN00112253)
1/8/2020		2107		Jacobson et al., Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review, J. Clin. Lipid. 6(1):5-18 (2012) (AMRN00302233)
1/8/2020		2108		Jan. 9, 2014 Comparative Literature Review of Statin Add-On Therapies Conducted by Amarin Pharma for the FDA DMEP (2014) (AMRN00540152)
1/8/2020		2109		Otvos, J. D. et al., Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial, Circulation;113, (2006) (AMRN00934595)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2110		American Diabetes Association Dyslipidemia Management in Adults with Diabetes, Diabetes Care, 27(Supp. 1) S68-S71 (2004) (AMRN01213101)
1/8/2020		2111		Downs, J. R. et al., Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of (AFCAPS/TexCAPS), JAMA;279(20); (1998) (AMRN01235590)
1/8/2020		2112		Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial, The Lancet 361 (2003) (AMRN01382864)
1/8/2020		2113		Miller et al., Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association, Circulation 2011;123:00-00 (2011) (AMRN02283764)
1/8/2020		2114		7/26/2012 Amarin Press Release (AMRN02488139)
1/8/2020		2115		Thies F. et al., Association of n-3 Polyunsaturated Fatty Acids with Stability of Atherosclerotic Plaques: a Randomised Controlled Trial, The Lancet, 361(9356) (2003) (AMRN02993597)
1/8/2020		2116		FDA Medical Review (AMRN03105942)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2117		Oct. 16, 2013 Amarin Briefing Materials Document for the Endocrinologic and Metabolic Drugs Advisory Committee (EDMAC) (2013) (AMRN03106618)
1/8/2020		2118		Mason et al., Eicosapentaenoic Acid Inhibits Oxidation of ApoB Containing Lipoprotein Particles of Different Size In-Vitro when Administered Alone or in Combination with Atorvastatin Active Metabolite Compared with Other Triglyceride-Lowering Agents, 68 J. Cardiovasc. Pharmacol. 33-39 (2016) (AMRN03130052)
1/8/2020		2119		Ballantyne, et al., Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients with Persistent High Triglycerides (from the ANCHOR Study), Am. J. Cardiol. 110:984-992 (2012) (AMRN03144838)
1/8/2020		2120		Ginsberg et al., Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus, 362 NEJM 1563, 1563 (2010) (AMRN03146139)
1/8/2020		2121		Supplementary Appendix to Bhatt (AMRN03164735)
1/8/2020		2122		Clinical Study Report: A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR 101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease REDUCE-IT (Reduction of



Date Marked	Date Admitted	Number	Witness	Description
				Cardiovascular Events with EPA – Intervention Trial (Feb. 27, 2019) (“REDUCE-IT Study Report”) (AMRN03168530)
1/8/2020		2123		American Diabetes Association Standards of Medical Care in Diabetes, Diabetes Care, 32(Supp. 1) S13-S61 (2009) (AMRN-PEXP-0000722)
1/8/2020		2124		American Diabetes Association Standards of Medical Care in Diabetes, Diabetes Care, 42(Supp. 1) S1-S193 (2019) (AMRN-PEXP-0007748)
1/8/2020		2125		Leading a New Paradigm in Cardiovascular Health Management (2/16/2017) <a href="https://investor.amarincorp.com/static-files/9c8a04ec-dda7-4e68-a52b-418a7a378f01">https://investor.amarincorp.com/static-files/9c8a04ec-dda7-4e68-a52b-418a7a378f01</a> (ICOSAPENT_DFNDT00017769-79)
1/8/2020		2126		Elam et al., The ACCORD-Lipid Study: Implications for Treatment of Dyslipidemia in Type 2 Diabetes Mellitus, Clin Lipidol. 691) (2011) 9-20 <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509601/pdf/nihms296246.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4509601/pdf/nihms296246.pdf</a> (ICOSAPENT_DFNDT00017840-61)
1/8/2020		2127		Pure EPA Vascepa® Now Available in New, Smaller Half-Gram Capsule Size, available at <a href="https://investor.amarincorp.com/static-files/17ffc8ce-9628-4950-bf43-c83866820f4e">https://investor.amarincorp.com/static-files/17ffc8ce-9628-4950-bf43-c83866820f4e</a> (ICOSAPENT_DFNDT00018001-03)
1/8/2020		2128		2019 ACC/AHA Multi-Society Guidelines at 4, available at <a href="https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000678">https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000678</a> (ICOSAPENT_DFNDT00017650-747)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2129		LeRoith et al., Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline, J. Clin. Endocrinol. Metab. 104(5):1520-1574 (2019), available at <a href="https://academic.oup.com/jcem/article/104/5/1520/5413486">https://academic.oup.com/jcem/article/104/5/1520/5413486</a> (ICOSAPENT_DFNDT00017935-89)
1/8/2020		2130		Cymet, Tyler, Should We Treat Moderately Elevated Triglycerides?, Am. Fam. Physician 83(3):246-248 (2011), available at <a href="https://www.aafp.org/afp/2011/0201/p246.html">https://www.aafp.org/afp/2011/0201/p246.html</a> (ICOSAPENT_DFNDT00017821-22)
1/8/2020		2131		Hartz, et al., Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care, J. Endocr. Soc. 2(6) 497-512 (2018) ("Hartz"), available at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961027/pdf/js.2018-00079.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961027/pdf/js.2018-00079.pdf</a> (ICOSAPENT_DFNDT00017908-23)
1/8/2020		2132		Complaint, In re Certain Synthetically Produced, Predominantly EPA Omega-3 Products In Ethyl Ester Or Re-esterified Triglyceride Form, 337-TA-3247 (USITC Aug. 30, 2017) (ICOSAPENT_DFNDT00018382-503)
1/8/2020		2133		Amarin Pharma, Inc. v. ITC, No. 2018-1247, 2019 U.S. App. LEXIS 13136 (Fed. Cir. May 1, 2019) (ICOSAPENT_DFNDT00018315-32)
1/8/2020		2134		2019 ADA Guidelines March 27, 2019 Supplement, Section 10, Annotation ("2019 ADA Guidelines Supplement"), available at <a href="http://care.diabetesjournals.org/content/42/Supplement_1/S103">http://care.diabetesjournals.org/content/42/Supplement_1/S103</a>
1/8/2020		2135		Miller, Michael, Question: Is it safe to combine statins and fibrates? (2007),

Date Marked	Date Admitted	Number	Witness	Description
				available at <a href="https://www.medscape.org/viewarticle/563490">https://www.medscape.org/viewarticle/563490</a> (ICOSAPENT DFNDT00017993-94)
1/8/2020		2136		Shek, et al., Statin-fibrate combination therapy, Ann. Pharmacother. 35(7-8):908-17 (2001), available at <a href="https://www.ncbi.nlm.nih.gov/pubmed/11485144">https://www.ncbi.nlm.nih.gov/pubmed/11485144</a> (ICOSAPENT DFNDT00018004-05)
1/8/2020		2137		Berglund et al., Treatment Options for Hypertriglyceridemia: from Risk Reduction to Pancreatitis, Best Pract Res Clin Endocrinol Metab. 28(3):423-427 available at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028601/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028601/</a> (ICOSAPENT DFNDT00016834-43)
1/8/2020		2138		Kris-Etherton, P. M. et al., Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease, Circulation 106:2747-2757, available at <a href="https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000038493.65177.94">https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000038493.65177.94</a> ; impeachment (ICOSAPENT DFNDT00017924-34)
1/8/2020		2139		Dr. Matthew Budoff, Understanding How Vascepa Fits in the Prescription-Based, Pure EPA Market in Treating Hypertriglyceridemia, Slingshot Insights (2017) 1-15 (ICOSAPENT DFNDT00018048-62)
1/8/2020		2140		Dr. Matthew Budoff, Preparing for Amarin's REDUCE-IT Data Read Out for Vascepa in Patients with Elevated Cardiovascular Risk, Slingshot Insights (2018) (ICOSAPENT DFNDT00017823-39)
1/8/2020		2141		Brinton, E. A. and Mason, R. P., Prescription Omega-3 Fatty Acid

Date Marked	Date Admitted	Number	Witness	Description
				Products Containing Highly Purified Eicosapentaenoic Acid (EPA), Lipids in Health and Disease, 16(1) (2017) available at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282870/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282870/</a> (ICOSAPENT_DFNDT00017808-20)
1/8/2020		2142		What is Amarin's Opinion on the ASCEND Clinical Trial (2018), available at <a href="https://investor.amarincorp.com/static-files/7cb6fad5-e22b-4d15-98b9-28eb4c43f95f">https://investor.amarincorp.com/static-files/7cb6fad5-e22b-4d15-98b9-28eb4c43f95f</a> (ICOSAPENT_DFNDT00018045-47)
1/8/2020		2143		Terano, T. et al., Eicosapentaenoic Acid as a Modulator of Inflammation, Biochemical Pharmacology, 35(5), (1986) 779-785 (ICOSAPENT_DFNDT00016823-29)
1/8/2020		2144		Surette, M. E., The Science Behind Dietary Omega-3 Fatty Acids, CMAJ, 178(2)(2008) 177-180, available at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174995/pdf/20080115s00023p177.pdf">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174995/pdf/20080115s00023p177.pdf</a> (ICOSAPENT_DFNDT00018024-27)
1/8/2020		2145		Omura, M. et al., Eicosapentaenoic Acid (EPA) Induces Ca <sup>2+</sup> -Independent Activation and Translocation of Endothelial Nitric Oxide Synthase and Endothelium-Dependent Vasorelaxation, FEBS Letters, 487(3), 361-366 (2001) available at <a href="https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/S0014-5793%2800%2902351-6">https://febs.onlinelibrary.wiley.com/doi/epdf/10.1016/S0014-5793%2800%2902351-6</a> (ICOSAPENT_DFNDT00017995-8000)
1/8/2020		2146		Suzuki, T. et al., Eicosapentaenoic Acid Protects Endothelial Cells Against

Date Marked	Date Admitted	Number	Witness	Description
				Anoikis Through Restoration of cFLIP, Hypertension, 42, 342-348 (2003) available at <a href="https://www.ahajournals.org/doi/pdf/10.1161/01.HYP.0000084602.06114.AD">https://www.ahajournals.org/doi/pdf/10.1161/01.HYP.0000084602.06114.AD</a> (ICOSAPENT DFNDT00018028-34)
1/8/2020		2147		Executed Research Proposal, Comparative Inhibition of Oxidation for EPA versus DHA and an EPA/DHA Combination in High Density Lipoproteins (HDL) (AMRN03171442-52)
1/8/2020		2148		Research Agreement between Amarin, APIL and Elucida (AMRN03171453-70)
1/8/2020		2149		Executed Research Proposal, Comparative Inhibition of Oxidation for EPA versus DHA in Small Dense LDL (sdLDL): A Kinetics Analysis between Amarin and Elucida (AMRN03171471-77)
1/8/2020		2150		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA) versus Docosahexaenoic Acid (DHA) Human Endothelial Function between Amarin and Elucida (AMRN03171478-86)
1/8/2020		2151		Executed Schedule 1: Services -- Extension # 1 between Amarin and Elucida(AMRN03171487-88)
1/8/2020		2152		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) and Statins on Human Endothelial Function and Nitric Oxide Release: Basis for Synergistic Actions between Amarin and Elucida (AMRN03171489-99)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2153		Executed Research Services Agreement, Comparative Effects of Eicosapentaenoic Acid (EPA), Docosapentaenoic Acid (DPA) versus Docosahexaenoic Acid (DHA) and EPA/DHA on Membrane Domains: X-ray Diffraction Analysis between Amarin and Elucida (AMRN03171500-5120)
1/8/2020		2154		Executed Research Services Agreement, Synergistic Effects of Eicosapentaenoic Acid (EPA) and Statins in Human Endothelial Function, Schedule 1: Services between Amarin and Elucida (AMRN03171513-522)
1/8/2020		2155		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA) versus Docosahexaenoic Acid (DHA) and EPA/DHA on Membrane Domains: X-ray Diffraction Analysis, Schedule 1: Services between Amarin and Elucida (AMRN03171523-31)
1/8/2020		2156		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) on Cholesterol Crystal Domains in Membranes with Hyperglycemia: X-ray Diffraction Study, Schedule 1: Services between Amarin and Elucida (AMRN03171532-44)
1/8/2020		2157		Executed Research Proposal, Inhibition of Oxidation by Eicosapentaenoic Acid (EPA) in Human LDL Subfractions: A Focus on Small Dense LDL between Amarin and Elucida (AMRN03171545-55)
1/8/2020		2158		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Fenofibrate, Niacin, and Gemfibrozil - Alone or in Combination with Statins - on Oxidation of Small Dense and

Date Marked	Date Admitted	Number	Witness	Description
				Unfractionated Human Low Density Lipoprotein (LDL) between Amarin and Elucida(AMRN03171556-69)
1/8/2020		2159		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) versus Docosahexaenoic Acid (DHA), Fenofibrate, Niacin, and Gemfibrozil on Disruption of Established Membrane Cholesterol Domains between Amarin and Elucida (AMRN03171570-79)
1/8/2020		2160		Executed Research Proposal, Effects of Small Dense LDL on Human Endothelial Function after Treatment with Eicosapentaenoic Acid (EPA) - Alone or in Combination with Statin - Versus Fenofibrate, Niacin, Gemfibrozil and Docosahexaenoic Acid (DHA) Under Conditions of Oxidative Stress and more between Amarin and Elucida (AMRN03171580-90)
1/8/2020		2161		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Docosahexanoic Acid (DHA), Fenofibrate, Niacin, Gemfibrozil - Alone or in Combination with Atorvastatin Metabolite - on Human Endothelial Function Following Exposure to oxLDL between Amarin and Elucida (AMRN03171591-605)
1/8/2020		2162		Executed Research Proposal for Completion of BBA Manuscript, Dose-Dependent Effects of Vascepa between Amarin and Elucida (AMRN03171606-617)
1/8/2020		2163		Executed Research Proposal, Comparative Effects of

Date Marked	Date Admitted	Number	Witness	Description
				Eicosapentaenoic Acid (EPA), Fenofibrate, Niacin, and Gemfibrozil - Alone or in Combination with Select Statins - on Lipid Peroxidation in Model Membranes Exposed to Hyperglycemic Conditions and more between Amarin and Elucida (AMRN03171618-29)
1/8/2020		2164		Executed Research Proposal, Distinct Effect of EPA Plus/Minus Atorvastatin Active Metabolite on Inhibiting Rat Glomerular Endothelial Dysfunction with Hyperglycemia and oxLDL Ex Vivo: Comparison to other TG-Lowering Agents and DHA between Amarin and Elucida (AMRN03171630-639)
1/8/2020		2165		Executed Research Proposal, Comparative Effects of EPA vs DHA on membrane Lipid Dynamics and Structure: Fluorescence Anisotropy and X-Ray Diffraction Analyses between Amarin and Elucida (AMRN03171640-58)
1/8/2020		2166		Executed Research Proposal, Time-Dependent Effects of Eicosapentaenoic Acid (EPA) Pretreatment of HUVECS - Alone or in Combination with Atorvastatin Metabolite - versus Docosahexaenoic Acid (DHA), Fenofibrate, Niacin and Gemfibrozil on Endothelial Function with Oxidized LDL Exposure and more between Amarin and Elucida (AMRN03171659-69)
1/8/2020		2167		Executed Research Proposal, Dose Dependent Effects of Eicosapentaenoic Acid (EPA) on Disruption of Established Membrane Cholesterol Domains (AMRN03171670-78)



Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2168		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA) plus/minus Atorvastatin Active Metabolite (ATM) on Oxidation of Small Dense Human Low Density Lipoprotein (sdLDL) with Hyperglycemia (AMRN03171679-88)
1/8/2020		2169		Executed Research Proposal, Comparative Effects of EPA, DHA, Niacin, Fenofibrate and Vitamin E on Membrane Oxidation over a Broad Cholesterol Range under conditions of Hyperglycemia and more (AMRN03171689-97)
1/8/2020		2170		Executed Research Proposal, Comparative and Time-Dependent Effects of Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), EPA/DHA Combination and Vitamin E on sdLDL Oxidation(AMRN03171698-704)
1/8/2020		2171		Executed Research Proposal, Effects of Eicosapentaenoic Acid (EPA) - Alone or in Combination with the ortho-hydroxy metabolite of Atorvastatin and more (AMRN03171705-13)
1/8/2020		2172		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida (AMRN03171714-20)
1/8/2020		2173		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida (AMRN03171721-31)
1/8/2020		2174		Executed Services Agreement between Amarin and R. Preston Mason for

Date Marked	Date Admitted	Number	Witness	Description
				10/20/2015 - 10/26/2015 (AMRN03171732-34)
1/8/2020		2175		Amendment # 1 to The Research Services Agreement between Amarin, APIL, and Elucida (AMRN03171735-37)
1/8/2020		2176		Amarin Confidentiality Agreement between Amarin and R. Preston Mason (AMRN03171738-40)
1/8/2020		2177		Executed Schedule 1 Services (AMRN03171741-42)
1/8/2020		2178		Consultancy Agreement between Amarin and R. Preston Mason (AMRN03171743-51)
1/8/2020		2179		Services Agreement between Amarin and R. Preston Mason for 4/14/2016 - 6/30/2016 (AMRN03171752-56)
1/8/2020		2180		Services Agreement between Amarin and R. Preston Mason for 10/1/2015 - 11/6/2015 (AMRN03171757-59)
1/8/2020		2181		Mutual Confidentiality Agreement between Amarin and R. Preston Mason(AMRN03171760-62)
1/8/2020		2182		Amendment # 1 to The Research Services Agreement between Amarin,

Date Marked	Date Admitted	Number	Witness	Description
				APIL, and Elucida (AMRN03171763-83)
1/8/2020		2183		Executed IIT Study Review & Support Agreement Form - EPA Preserves HDL and Endothelial Function (AMRN03171784)
1/8/2020		2184		Executed IIT Study Review & Support Agreement Form - Comparative Inhibition of Oxidation for EPA versus DHA and an EPA/DHA Combination in High Density Lipoproteins (HDL) (AMRN03171785)
1/8/2020		2185		Services Agreement between Amarin and R. Preston Mason for 12/9/2016 - 1/15/2017 (AMRN03171786-90)
1/8/2020		2186		Services Agreement between Amarin and R. Preston Mason for 12/9/2016 - 1/15/2017 (AMRN03171791-95)
1/8/2020		2187		W-9 Form for Elucida Research LLC (AMRN03171796-804)
1/8/2020		2188		Executed Research Proposal, Comparative and Time-Dependent Effects of Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA), EPA/DHA Combination and Vitamin E on sdLDL Oxidation (AMRN03171805-11)
1/8/2020		2189		Executed Schedule 1 to The Research Services Agreement Between Amarin,

Date Marked	Date Admitted	Number	Witness	Description
				APIL, and Elucida - Comparative Inhibition of Eicosapentenoic Acid (EPA) versus Similar Fatty Acid on Membrane Oxidation - Addendum for Additional cholesterol crystal domain investigations (phase 2c) (AMRN03171812-15)
1/8/2020		2190		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Effects Eicosapentenoic Acid (EPA) in Combination with Atorvastatin and Compared to Docosahexanoic Acid (DHA) on Human Endothelial Cell Dysfunction Caused by Lipolzed TG-Rich Lipoprotein (VLDL)(AMRN03171816-20)
1/8/2020		2191		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Comparative Inhibition of Eicosapentenoic Acid (EPA) versus Similar Fatty Acid on Membrane Oxidation (AMRN03171821-32)
1/8/2020		2192		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Comparative Inhibition of Oxidation for EPA versus ETE, AA, EA, DHA, DPA, ALA, OA, LA, and SA in Human Small Dense LDL (sdLDL) (AMRN03171833-45)
1/8/2020		2193		Services Agreement between Amarin and R. Preston Mason for 1/1/2016 - 1/31/2016 (AMRN03171846-48)
1/8/2020		2194		Executed Research Proposal, Comparative Effects of Eicosapentaenoic Acid (EPA), Fenofibrate, Niacin, and Gemfibrozil - Alone or in Combination with Select

Date Marked	Date Admitted	Number	Witness	Description
				Statins - on Lipid Peroxidation in Model Membranes Exposed to Hyperglycemic Conditions and more between Amarin and Elucida (AMRN03171849-60)
1/8/2020		2195		Executed Schedule 1 to The Research Services Agreement Between Amarin, APIL, and Elucida - Effects of Eicosapentenoic Acid (EPA) on Human LDL and Model Membrane Oxidation: A Dose - ranging Analysis of Potential Threshold Activity in Vitro - Addendum for additional aliquotes, timepoints and concentrations (AMRN03171861-65)
1/8/2020		2196		Executed Research Proposal, Effects of Eicosapentenoic Acid (EPA) on Human LDL and Model Membrane Oxidation (AMRN03171866-79)
1/8/2020		2197		Executed Schedules between APIL, Amarin, and Elucida (AMRN03171880-81)
1/8/2020		2198		Executed Research Proposal, Comparative and Time-Dependent Effects of sdLDL Treated with either Eicosapentaenoic Acid (EPA) or Docosahexanoic Acid (DHA) under Oxidative Stress Conditions on Human Endothelial Function (AMRN03171882-94)
1/8/2020		2199		Ando, Eicosapent Acid Reduces Plasma Levels of Remnant Lipoproteins and Prevents in Vivo Peroxidation of LDL in Dialysis Patients. J Am Nephrol 10:2177 (1999) (ICOSAPENT_DFDTS00007276-83)
1/8/2020		2200		Chan, et al. Factorial study of the effects of atorvastatin and fish oil on

Date Marked	Date Admitted	Number	Witness	Description
				dyslipidaemia in visceral obesity. European Journal of Clinical Investigation 32:429-436 (2002) (ICOSAPENT_DFDTS00005926-35)
1/8/2020		2201		Contacos, et al. Effect of Pravastatin and w-3 Fatty Acids on Plasma Lipids and Lipoproteins in Patients With Combined Hyperlipidemia. Arterior Thromb Vasc Biol. 13:1755-1762 (1993) (ICOSAPENT_DFDTS00005944-52)
1/8/2020		2202		European Patent Application EP 0 273 708 A2 (ICOSAPENT_DFDTS00005953-76)
1/8/2020		2203		European Patent Application EP 0 277 747 A2 (ICOSAPENT_DFDTS00005977-83)
1/8/2020		2204		European Patent Application EP 0 347 509 A1 (ICOSAPENT_DFDTS00005984-96)
1/8/2020		2205		Kelley et al., Docosahexaenoic Acid Supplementation Improves Fasting and Postprandial Lipid Profiles in Hypertriglyceridemic Men, pp. 324-333, Clinical Nutrition, Volume 86, No. 2 (August 2007) (ICOSAPENT_DENDTS00006201-6212)
1/8/2020		2206		Leigh-Firbank, et al, Eicosapentaenoic Acid and Docosahexaenic Acid from Fish Oils: Differential Associations with Lipid Responses, British Journal of Nutrition (2002), Volume 87, pp. 435-445. (ICOSAPENT_DFNDTS00006245-55)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2207		Lovegrove, et al., Moderate Fish-oil Supplementation Reverses Low-Platelet, Long-chain n-3 Polyunsaturated Fatty Acid Status and Reduces Plasma Triacylglycerol Concentrations in British Indo-Asians, Clinical Nutrition Volume 79, pp. 974-982 (2004) (ICOSAPENT_DFNDTS00006383-91)
1/8/2020		2208		Mataki, et al., Effect of Eicosapentaenoic Acid in Combination with HMG-CoA Reductase Inhibitor on Lipid Metabolism, International Medical Journal, Vol. 5, No. 1, pp. 35-36 (March 1998) (ICOSAPENT_DFNDTS00006437-39)
1/8/2020		2209		Pownall, et al., Correlation of Serum Triglyceride and Its Reduction by $\omega$ -3 Fatty Acids with Lipid Transfer Activity and the Neutral Lipid Compositions of High-density and Low-density Lipoproteins, Atherosclerosis (1998) (ICOSAPENT_DFNDTS00011379-91)
1/8/2020		2210		Theobald, et al., LDL Cholesterol-raising Effect of Low-dose Docosahexaenoic Acid in Middle-aged Men and Women, Clinical Nutrition, Volume 79, No. 4, pp. 558-563 (April 2004) (ICOSAPENT_DFNDTS00006905-12)
1/8/2020		2211		U.S. Patent 5,215,630 (ICOSAPENT_DFDTS00012204-214)
1/8/2020		2212		U.S. Patent 5,840,944 (ICOSAPENT_DFDTS00012337-343)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2213		U.S. Patent 6,303,330 (ICOSAPENT_DFDTS00005855-62)
1/8/2020		2214		U.S. Patent 6,384,077 (ICOSAPENT_DFDTS00007000-13)
1/8/2020		2215		U.S. Patent 6,846,942 (ICOSAPENT_DFDTS00005863-67)
1/8/2020		2216		U.S. Patent Application Publication 2003/0104048(ICOSAPENT_DFDTS0 0006913-45)
1/8/2020		2217		U.S. Patent Application Publication 2006/0134178 (ICOSAPENT_DFDTS00006946-63)
1/8/2020		2218		Virani and Nambi, The Role of Lipoprotein-associated Phospholipase A2 As a Marker for Atherosclerosis. Current Atherosclerosis Reports 9:97- 103 (ICOSAPENT_DFDTS00007014-20)
1/8/2020		2219		Rader, Lipid Disorders. In Textbook of Cardiovascular Medicine, Chapter 5 (3d ed. 2007) (AMRN0290951-973)
1/8/2020		2220		Sanders, Triglyceride-Lowering Effect of Marine Polyunsaturates in Patients with Hypertriglyceridemia. Arteriosclerosis 5:459-465 (1985) (AMRN0291030-1036)



Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2221		Nicholas P. Godici Curriculum Vitae
1/8/2020		2222		Jay W. Heinecke, M.D. Curriculum Vitae
1/8/2020		2223		Ivan T. Hofmann Curriculum Vitae
1/8/2020		2224		John Kornak, PhD Curriculum Vitae
1/8/2020		2225		Jonathan I. Sheinberg, MD, FACC Curriculum Vitae
1/8/2020		2226		Endocrinologic and Metabolic Drugs Advisory Committee Briefing Document: Vascepa® REDUCE-IT® (Reduction of Cardiovascular Events with EPA - Intervention Trial)
1/8/2020		2227		Errata to the Amarin Pharmaceutical Ireland Limited (Amarin) Briefing Document for the Advisory Committee meeting on 14 November 2019.
1/8/2020		2228		FDA Briefing Document, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting, November 14, 2019

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2229		Erratum to FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee (EDMAC) Meeting, November 14, 2019
1/8/2020		2230		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Roster
1/8/2020		2231		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, November 14, 2019, Draft Agenda
1/8/2020		2232		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, November 14, 2019, Draft Meeting Roster
1/8/2020		2233		Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting, November 14, 2019, Draft Questions
1/8/2020		2234		November 14, 2019 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Information
1/8/2020		2235		Icosapent Ethyl (VASCEPA®): Amarin Pharmaceuticals Presentation to the Endocrinologic and Metabolic Drugs Advisory Committee, NDA 202057
1/8/2020		2236		FDA Introductory Remarks, Endocrinologic and Metabolic Drugs,

Date Marked	Date Admitted	Number	Witness	Description
				Advisory Committee (EMDAC) Meeting, John Sharretts, M.D.
1/8/2020		2237		Plaintiffs' Responses and Objections to Defendants' Joint First Set of Interrogatories to Amarin (Nos. 1-8)
1/8/2020		2238		November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Start of Meeting to Morning Break. <a href="https://collaboration.fda.gov/poku8qu000zj/?launcher=false&amp;fcsContent=true&amp;pbMode=normal">https://collaboration.fda.gov/poku8qu000zj/?launcher=false&amp;fcsContent=true&amp;pbMode=normal</a>
1/8/2020		2239		November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Morning Break to Afternoon Break. <a href="https://collaboration.fda.gov/pgu58b2olhgv/?launcher=false&amp;fcsContent=true&amp;pbMode=normal">https://collaboration.fda.gov/pgu58b2olhgv/?launcher=false&amp;fcsContent=true&amp;pbMode=normal</a>
1/8/2020		2240		November 14, 2019, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) - Webcast Recording, Afternoon Break to End of Meeting. <a href="https://collaboration.fda.gov/pegir9sba12n/?launcher=false&amp;fcsContent=true&amp;pbMode=normal">https://collaboration.fda.gov/pegir9sba12n/?launcher=false&amp;fcsContent=true&amp;pbMode=normal</a>
1/8/2020		2241		AMRN00731643 Metadata
1/8/2020		2242		Vascepa sNDA annotated label (AMRN03174152-3174172)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2243		Vascepa sNDA approval (AMRN03174932-3174950)
1/8/2020		2244		Vascepa sNDA Clinical Overview(AMRN03174702-3174749)
1/8/2020		2245		Vascepa sNDA Clinical Pharmacology (AMRN03174826-3174835)
1/8/2020		2246		Vascepa sNDA Financial Disclosure (AMRN03174601-3174666)
1/8/2020		2247		Vascepa sNDA label (AMRN03174410-3174423)
1/8/2020		2248		Vascepa sNDA label (AMRN03174954-3174967)
1/8/2020		2249		Vascepa sNDA labeling correspondence (AMRN03175000-3175298)
1/8/2020		2250		Vascepa sNDA patent forms (AMRN03174514-3174597)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2251		Vascepa sNDA Reviewer Guide (AMRN03174505-3174513)
1/8/2020		2252		Vascepa sNDA Summary of Clinical Efficacy (AMRN03174762-3174825)
1/8/2020		2253		Amarin News - General Release - Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa® (icosapent ethyl) Capsules (WWICO-NV-148504-148506)
1/8/2020		2254		VASCEPA - Exclusivity Determination
1/8/2020		2255		Amarin News - General Release - Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa® (icosapent ethyl) Capsules
1/8/2020		2256		Icosapent Ethyl 1g Capsules Labeling (WWICO-NV-162529-162539)
1/8/2020		2257		RLD Side-By-Side Comparison (WWICO-NV-162550-162564)
1/8/2020		2258		Woodman, et al., Docosahexaenoic Acid but Not Eicosapentaenoic Acid

Date Marked	Date Admitted	Number	Witness	Description
				Increases LDL Particle Size in Treated Hypertensive Type 2 Diabetic Patients, 26 Diabetes Care 253 (2003) ("Woodman 2003b") (AMRN01066627)
1/8/2020		2259		Woodman, et al., Effects of Purified Eicosapentaenoic Acid and Docosahexaenoic Acid on Platelet, Fibrinolytic and Vascular Function in Type 2 Diabetic Patients, 166 Atherosclerosis 85 (2003) ("Woodman 2003a") (AMRN01172851-1172859)
1/8/2020		2260		Mori et al., Docosahexaenoic Acid but Not Eicosapentaenoic Acid Lowers Ambulatory Blood Pressure and Heart Rate in Humans, 34 Hypertension 253 (1999) ("Mori 1999") (AMRN01177185-1177193)
1/8/2020		2261		Hamazaki et al., Docosahexaenoic Acid-Rich Fish Oil Does Not Affect Serum Lipid Concentrations of Normolipidemic Young Adults, 126 J. Nutrition 2784 (1996) ("Hamazaki") (AMRN-PEXP-0007332-7337)
1/8/2020		2262		Nelson et al., The Effect of Dietary Docosahexaenoic Acid on Plasma Lipoproteins and Tissue Fatty Acid Composition in Humans, 32 Lipids 1137 (1997) ("Nelson") (AMRN00290858-290867)
1/8/2020		2263		Woodman et al., Effects of Purified Eicosapentaenoic and Docosahexaenoic Acids on Glycemic Control, Blood Pressure, and Serum Lipids in Type 2 Diabetic Patients with Treated Hypertension, 76 Am. J. Clinical Nutrition 1007 (2002) ("Woodman 2002") (AMRN00291334-291342)

Date Marked	Date Admitted	Number	Witness	Description
1/8/2020		2264		Grimsgaard et al., Effects of Highly Purified Eicosapentaenoic Acid and Docosahexaenoic Acid on Hemodynamics in Humans, 68 Am. J. Clinical Nutrition 52 (1998) ("Grimsgaard 1998") (ICOSAPENT-DFNDTS00009272-9279)
1/8/2020		2265		AMRN01171835-1171859 Metadata